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Abstract
The field of molecular imaging is constantly growing and evolving in order to provide the
best possible healthcare for patients in various stages of disease and therapy. Molecular
imaging aims to locate specific markers of disease by selectively targeting the markers of
interest with high selectivity and visualizing the accumulation using external detection.
The growth hormone secretagogue receptor-1a (GHS-R1a) has been shown to be involved in
various important biological functions such as energy homeostasis and cardiac contractility.
GHS-R1a has shown involvement in proliferation, migration and cell invasion of specific
cancer subtypes. Therefore, targeting GHS-R1a is an important marker of different disease
states and would be advantageous to selectively target for diagnostic and therapeutic
purposes.
This thesis will document the development of peptide-based molecular imaging agents
capable of targeting GHS-R1a with high affinity designed off the structure of ghrelin, the
endogenous ligand for GHS-R1a.
Chapter 2 discusses the synthesis and evaluation of gallium-69/71 and gallium-68 labelled
ghrelin(1-19) analogues. The first generation of ghrelin analogues was designed to detect
GHS-R1a by positron emission tomography (PET). Chelation of gallium had a positive effect
on binding affinity to GHS-R1a resulting in an IC50 comparable to natural ghrelin(1-28).
Preclinical evaluation of HT1080/GHSR-1a xenografts showed higher SUVR values than the
HT1080 xenograft with no GHS-R1a.
Chapter 3 discusses the second generation of ghrelin analogues that were further truncated to
eight amino acids. A structural activity study investigated residues 1, 3, 4, and 8 to determine
whether amino acid substitutions produce the best binding affinity GHS-R1a. The optimized
ghrelin analogue has 12-fold higher binding affinity to GHS-R1a than natural ghrelin. New
radiochemical syntheses were reported for a 6-[18F]-fluoro-2-pentafluorophenylnaphthoate
prosthetic group. The lead peptide analogue was radiolabelled in a 3% radiochemical yield
and resulted in the first fluorine-18 labelled ghrelin(1-8) analogue with greater affinity to
GHS-R1a.

The final chapter describes the effects of targeting GHS-R1a with a dimerized ghrelin(1-8)
peptide. Dimerizing other peptide targeting entities has increased binding affinity to the
target however, this is not the case found with ghrelin. The in vitro kinetics were evaluated
using fluorescence microscopy in GHS-R1a expressing cells.
All three chapters discuss the systematic modification of an endogenous peptide ligand into a
high affinity, PET imaging agent through classical methods of peptide modification and
radiochemistry.

Keywords
Ghrelin, GHS-R1a, Peptide, Molecular Imaging, PET, Optical Imaging, Solid-Phase Peptide
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Chapter 1

1

Introduction

1.1 Peptides and Molecular Imaging
The complexity of all living systems is a daunting task to understand. Yet, when broken
down into fundamental building blocks, the complexity of these systems appears to be an
eloquent work of art. One fundamental building block of all complex living systems is
peptides. Found in all living systems, peptides are diverse naturally occurring compounds
responsible for many biological functions. They are capable of acting as
neurotransmitters, growth factors or antimicrobials, as well as facilitating cell-to-cell
communication and ion-channel regulation, to name only a few.

Peptides fit a

specialized niche between the two molecular weight extremes of small molecules and
proteins. They are able to combine the benefits of small molecules, such as low cost,
membrane permeability and metabolic stability, with target specificity and high potency
seen in proteins and antibodies. More importantly, peptides and their endogenous
receptors have been implicated in disease states such as oncology, metabolic disorders
and cardiovascular disease.1
Natural peptides, composed entirely of natural components, are known to have a
relatively short in vivo half-life and are readily metabolized by endo- and exo- peptidases.
Fortunately, peptides can be easily manipulated to increase in vivo stability, membrane
permeability and target selectivity using well-known methods. These methods have been
applied to many natural peptides to target their endogenous receptors for diagnosis and
therapeutic applications. In order to detect these natural peptides externally, they must be
modified to contain a signalling source capable of being detected with the various
molecular imaging modalities. Molecular imaging modalities commonly used in both
preclinical and clinical settings are positron emission tomography (PET), single-photon
emission computed tomography (SPECT), magnetic resonance imaging (MRI),
ultrasound (US) and optical imaging (OI). Each modality has their own strengths and
weaknesses with respect to imaging sensitivity and spatial resolution.2 In comparison to
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the other modalities, PET has attractive attributes due to its high image sensitivity and
requires radionuclides as a signalling source that have suitable attributes for diagnostic
molecular imaging. Optical imaging is another imaging modality with high image
sensitivity that doesn’t require a radioactive signalling source. The commonly used
methods to incorporate PET and OI signalling sources into natural peptides, as well as the
many approaches to modifying these peptides for improved in vivo pharmacokinetics will
be outlined.

1.2 Suitable Signaling Sources for PET and OI
Peptide-based targeting entities are a versatile class of radiopharmaceuticals able to
selectively target receptors within the human body, allowing for a disease to be detected,
staged, or treated. External monitoring of radiolabelled targeting entities can be achieved
via a sensitive molecular imaging modality currently used in nuclear medicine: PET.1
PET has slowly gained popularity since its discovery in the 1960’s and has since become
clinically acceptable. This modality requires a radionuclide to emit photons in the form of
radiation, which can then be externally detected and processed into an image. PET
requires radionuclides that decay via positron emission (Table 1.1). Once a positron is
ejected from the nucleus, it travels a short distance before colliding with an electron. An
annihilation event produces two 511 keV gamma rays emitted at a coincidence angle of
180o and are simultaneously detected by two scintillation detectors (Figure 1.1).
Table 1.1 Common PET radionuclides and half-lives.
Isotope

Half-life

Carbon-11

20.4 m

Copper-64

12.7 h

Fluorine-18

109.7 m

Gallium-68

68 m

Nitrogen-13

9.96 m

Oxygen-15

2.07 m

Yttrium-86

14.7 m

Zirconium-89

3.27 d

3

Figure 1.1 Depiction of an annihilation event within a PET Scanner. A β+ emitting radioisotope ejects a
positron from its nucleus that meets an electron. Upon contact, the positron and electron undergo an
annihilation event resulting in two 511 keV gamma rays being emitted approximately 180° apart. The
emitted gamma rays are detected by a ring of scintillation detectors and further processed into a PET
image.

There are a number of radioisotopes that have applications in PET imaging. The most
prevalent PET radioisotope, as well as the most important isotope in the
radiopharmaceutical industry due to 2-deoxy-2’-fluoro-D-glucose (FGD), is fluorine-18
(18F). F-18 is a cyclotron-produced radioisotope made from an oxygen-18 (18O) enriched
target. The half-life of 110 minutes allows the isotope to be made off-site and shipped to
facilities for use. Most commonly the radioisotope is shipped as synthesized [18F]-FDG.
[18F]-FDG is used to monitor glucose metabolism and has gained popularity in the field
of oncology due to the high metabolic activity observed in most types of malignant
tumours. [18F]-FDG can also be used to monitor treatment regimens. Unfortunately, [18F]FDG uptake is not specific to tumours, but is also taken up by areas of natural high
glucose metabolism such as the brain and kidney. Therefore, there is interest in
developing a peptide-based targeting agent that bears fluorine-18 and can achieve higher
specificity for its target. Due to the small atomic radius of fluorine, it can be integrated
into many biomolecules without greatly affecting the binding region. Fluorine-18 has
been integrated into most natural peptides such as somatostatin, α-melanocyte stimulating
hormone (MSH), neurotensin, RGD, and bombesin.3,
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In addition to fluorine, carbon,
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which is known for its ability to form a vast number of compounds, also has a radioactive
isotope, carbon-11 (11C). Carbon-11 has a short half-life of 20.4 minutes and can be
incorporated into many molecules resulting in a negligible isotope effect. Due to its halflife, it is most suited for short-lived radiopharmaceuticals in facilities that have access to
an in-house cyclotron. Gallium-68 (68Ga) is an additional radiometal with a 68-minute
half-life that is gaining popularity as a PET isotope. The parent isotope, germanium-68
(68Ge), has a 271-day half-life, allowing it to be packaged into a 68Ge/68Ga generator that
functions similarly to the

99

Mo/99mTc generators. Since germanium-68 has a long half-

life, these generators can last over a year before being replaced. The most common use
for gallium-68 is DOTA-TOC, a peptide-based imaging agent used to target somatostatin
receptors in neuroendocrine tumours.5,6
The choice of radionuclide is dependent on the half-life, availability, method of
incorporation, and method of radioactive decay. The half-life must be long enough to
withstand synthesis, administration and distribution of the probe while maintaining
enough radioactivity to be detectable by the imaging modality. The availability and
proximity of a cyclotron limits the choice of radionuclides to generator-produced isotopes
that can be produced on-site. There are different methods for incorporating a radioisotope
that will be mentioned later on. The positron emission energy is an important aspect of
PET imaging. Isotopes with lower positron emission energy, usually measured in electron
volts (eV), produce images with higher resolution than those with higher positron
emission energy.
On the other hand, optical imaging is a low cost, high sensitivity and facile method of
molecular imaging. In order to successfully synthesize an optical imaging agent, a
targeting entity must contain a fluorophore signaling source for external detection.7
Fluorophores used in the early development of optical imaging emitted photons of 300 to
600 nm after excitation by an external source. Unfortunately, due to the many structures
within a cell, the scattering and absorption of the shorter photons in the visible region
limited the use of these fluorophores for in vivo applications. Longer wavelengths in the
near-infrared (NIR) region of 600 to 900 nm are less likely to be absorbed and scattered
by the structures within cells. This allows photons emitted in the NIR region to penetrate
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tissue several centimeters deep.8 These longer wavelengths are capable of penetrating
tissues and expand the use of fluorescence to in vivo applications that were not previously
applicable.9
With respect to oncology, optical imaging and the other molecular imaging modalities
have made large advancements with respect to tumour detection, staging and treatment
using targeted imaging modalities, such as peptides. When it comes to removal of
cancerous tissues by surgery, translation of the information gained from a PET, SPECT
or MRI image can be difficult to apply to the operation field.10 This makes complete
resection of a tumour difficult and leads to a chance of disease reoccurrence.11 NIR-OI
has been used to effectively address this issue. NIR-OI has the adequate image resolution
and tissue visualization required for real-time fluorescence imaging that can be used to
distinguish between cancerous and healthy tissue not apparent to the naked eye.10 Using
this technique, surgeons can effectively visualize and remove the cancerous tissue leaving
all healthy tissues intact and limiting the chance of disease reoccurrence. One example of
this was evaluated in colonic dysplasia using an octapeptide, QPIHPNNM, bearing a NIR
Cyanine-5.5 (Cy-5.5) dye.12 Using real time fluorescence imaging, NIR images were
collected endoscopically in mice with colonic dysplasia. There was significant contrast
between areas of dysplasia and normal colonic mucosa not visualized in the white light
image.12

1.3 Methods for Adding Radionuclides to Peptides
In an ideal situation, a radionuclide would be added into a natural peptide sequence
without changing the biological behaviour of the peptide, such as binding to a protein
receptor. This is generally not the case and different methods of incorporation have
varying levels of effect on binding affinity. Addition of a radionuclide can be achieved in
four general ways: pendant labelling, integrated labelling, prosthetic group incorporation,
or direct labelling (Figure 1.2). Most commonly, radiometals are attached to peptides
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through pendant labelling. This method requires a bifunctional metal chelator to be

Figure 1.2 Various methods for introducing a radioisotope into a peptide sequence: pendant labelling,
prosthetic group labelling, direct labelling and integrated labelling.

appended to the peptide sequence; bifunctional in that the chelator can be attached to the
peptide and also can coordinate a metal. Cyclic chelators, such as 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane1,4,7-trisacetic acid (NOTA), are used for radiometals including

67

Ga,

68

Ga, and

64

Cu.

Acyclic multidentate chelators such as diethylene triamine pentaacetic acid (DTPA) and
6-hydrazinonicotinic acid (HYNIC) analogues, can also be used (Figure 1.3).13-15 It is
challenging to incorporate these chelators into a peptide without having a detrimental
effect upon the ability of the peptide to target a protein receptor. Due to the size of the
chelation moiety, it must be located away from the binding region within the sequence to
avoid steric interactions or other undesirable non-covalent interactions with the receptor.
To achieve this distance, the chelators are often placed at the N- or C-terminus of the
peptide, on an amino acid side chain such as lysine, or following an aliphatic spacer. This
additional linkage increases the molecular weight of the peptide and is therefore not an
ideal way to radiolabel small targeting peptides. Integrated labelling, on the other hand,
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aims to hide a radiometal within the targeting peptide resulting in the metal being a key
structural component of the peptide. One approach to this is to have the metal induce
secondary structure formation, such as cyclization of the peptide, around the isotope.
Examples of this method are used for cyclization of natural peptides such as
gonadotropin-releasing hormone and somatostatin during technetium chelation.16-18 This
mode of concealing the isotope within the peptide would ideally have little effect on the
binding affinity of the targeting entity. The third method for radiolabelling a peptide is
the prosthetic group labelling approach, which is ideal for radionuclides with lower
atomic mass, such as

18

F and

11

C. A small molecule is developed as a precursor for

radiolabelling that can be easily incorporated into an amino acid side chain in one or two
synthetic steps. This method often includes purification and deprotection steps to achieve
a final pure radiolabelled peptide. In order to retain radiochemical yield, time efficient
and high yielding reactions must be used for every synthetic step, especially when
working with short-lived radionuclides. The most common synthetic approaches for
incorporating fluorine-18 into a prosthetic group are nucleophilic acyl substitution and
nucleophilic aromatic substitution.19,20 The development of bioorthogonal chemistry has
led to high yielding, high specificity reactions capable of incorporating a radiolabelled
prosthetic group into a natural peptide sequence. These reactions include Staudinger
ligation, azide-alkyne Huisgen cycloaddition, and inverse demand Diels-Alder
cycloadditions.21, 22 Prosthetic group labelling has led to increases in reaction rates and
yields; however, the numerous synthetic and purification steps required are detrimental to
overall radiochemical yields. In order to further improve radiochemical yields, a direct
labelling approach has become increasingly popular. This method places a radionuclide
on a modified amino acid side chain using a simple one-step reaction. However, the main
challenge with this method is to obtain site specific radiolabelling without disrupting the
functionality of the side chains, which may contain amines, carboxylic acids or amides
that are found in most peptide sequences. The direct labelling method has had varying
success with respect to radiochemical yields, with a variety of approaches being
described, including: di-tert-butylsilyl functionalized bombesin analogues, one-step
nucleophilic aromatic substitution with a trimethylammonium leaving group, chelation of
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[18F] aluminium fluoride, and nucleophilic aromatic substitution on an aromatic ring with
a nitro leaving group containing withdrawing groups in ortho and para positions. 23-25

Figure 1.3 Common cyclic and acyclic chelators capable of chelating various radiometals: (A) 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), (B) 1,4,7-triazacyclononane-1,4,7,-trisacetic acid
(NOTA), (C) diethylenetriamine-N,N,N’,N’,N’’’-pentaacetic acid (DTPA), (D) 6-hydrozinonicotinic acid
(HYNIC).

1.4 Modifying Radiolabelled Peptides for Improved In Vivo
Stability and Target Affinity
Peptides as targeting vectors offer many advantages with respect to other molecules, but
of course come with their own set of limitations. Natural peptides are known to have poor
oral bioavailability as well as low metabolic stability in vivo. Poor oral bioavailability is
less of a concern for imaging agents as opposed to therapeutic drugs, since
radiopharmaceuticals are typically administered intravenously, while poor metabolic
stability can be overcome using structural modifications designed to inhibit enzymatic
degradation. Peptides are often degradade by exopeptidases, enzymes that specifically
hydrolyze the C- and N-termini of a linear peptide. In order to resist exopeptidase
degradation, the functionality of the termini can be altered. The simplest approach is to
have the C-terminus synthesized as an amide and the N-terminus acetylated. Degradation
by exopeptidases can also be countered by head-to-tail cyclization, which removes the
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termini completely. Endopeptidases that are capable of hydrolyzing peptide bonds within
a peptide sequence are also of concern. Endopeptidases are only able to recognize natural
L-amino

acids; therefore replacing positions of hydrolysis with D-amino acid or unnatural

amino acid residues causes the peptides to become unrecognizable to the peptidase.
Contrary to the standard alpha-(α) amino acids, unnatural beta-(β) and gamma-(γ) amino
acid substitutions have the ability to arrange amino acid side chains into specific threedimensional conformations, tending to form helical and pleated sheet-like structural
motifs (Figure 1.4).26 These small structural modifications result in greater in vivo
stability, while the peptide sequence remains virtually unchanged, allowing it to maintain
target affinity.
L-amino acid

D-amino acid

COO
H3N

COO

H

H

R
α-amino acid
CO2-

H3N
R

NH3
R
γ-amino acid

β2-amino acid
CO2-

H3N
R

CO2-

H3N
R

Figure 1.4 Stereochemistry of natural L-amino acids as well as unnatural D-amino acids, α-amino acids,
β-amino acids, and γ-amino acids. R represents the applicable amino acid side chains.

A more complex method to increasing in vivo stability is to employ the pseudo-peptide
approach. Pseudo-peptides resemble the natural peptide structure, but contain chemical
modifications to the backbone that render them unrecognizable to peptidases. Some
examples include peptoids, aza-peptides, and amide-bond surrogates as shown in Figure
1.5. Peptoids, also known as N-substituted glycine’s, have not only been found to
increase peptide stability but also increase cell permeability by 20-fold compared to the
analogous peptide sequence. Attachment of the peptide side chains to the backbone
nitrogen eliminates the polar N-H bond causing an increase in lipophilicity, and in turn,
an increase in cell permeability.26 Aza-peptides, which replace one or more alpha-carbons
with a nitrogen atom, have been shown to result in a loss of stereogenicity and reduced
flexibility by replacing the rotatable αC-C(O) bond with a more rigid αN-C(O) bond.
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This reduction in flexibility has shown turn-inducing capabilities when the aza-residue is
placed in the i+1 or i+2 position favouring beta-turn conformations.27,

28

Amide bond

surrogates are designed to mimic the geometric structure of a peptide bond as well as
maintaining the positioning of side chains. Well known amide bond surrogates include
thioamides, esters, alkenes and fluoroalkenes but could be more detrimental to in vivo
stability. Thioamides are the most closely related surrogate to the standard amide bond
based on its number of atoms and the arrangement of valence electrons. Sulphur is a poor
hydrogen bond acceptor compared to oxygen, but the nitrogen proton maintains hydrogen
bond donation when part of a thioamide. Ester substitutions, although geometrically
similar to amide bonds, are not able to undergo hydrogen bond donation and act as poor
hydrogen bond acceptors, resulting in poor stability of secondary structure. More
importantly, esters are vulnerable to hydrolysis in vivo and are therefore not an attractive
surrogate. Alkene surrogates, on the other hand, completely lack a heteroatom capable of
non-covalent interactions but remain a popular peptide bond substitution due to their
ability to accurately mimic rigidity, bond angle, and bond length. It must be noted that
alkenes are susceptible to isomerization, oxidation and chemical liability in vivo;
however, they have been successfully incorporated into natural peptides such as the
tripeptide RGD and C-X-C chemokine receptor 4 CXCR4.29,

30

Heterocyclic moieties,

such as 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-triazole and 1,2,3-triazole are also used
as amide bond mimics.31, 32 A variety of strategies can be used to increase in vivo stability
of natural peptides ranging from simply exchanging

L

and

D

amino acids to more

complex substitution of pseudo-peptides. Each approach is accompanied by its own
advantages and disadvantages dependent on the natural peptide, target, and mode of
action. Finding the optimal peptide analogue can require various permutations in peptide
structure and the preparation and analysis of large libraries of peptide analogues is
advantageous for discovering the most suitable candidate.
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Figure 1.5 Various backbone modifications to alter in vivo stability of natural peptides. R represents
various amino acid side chains.

Much of the development of receptor targeting peptides has focused on receptor agonists.
Agonists are known to possess high binding affinities for their receptors that trigger
internalization of the ligand-receptor complex. It was rationalized that the internalization
and accumulation of the radioligand in the cell over time would lead to better target-tobackground ratios and overall a better radiopharmaceutical. It wasn’t until the late 1990’s
that attention began to shift from agonists to potent antagonists. Antagonists are capable
of binding orthosteric and/or allosteric sites on a receptor without eliciting a biological
response and therefore, are not internalized, as agonists would be. Comparative studies
show that antagonists have better chemical stability and longer duration of action than an
agonist as well as binding can persist up to 8 days.33 Many well-known receptor targets
have been investigated for antagonist ligands and have resulted in improved stability and
in vivo stability.

1.5 Modifying Natural Peptides for Improved
Pharmacokinetics
The success of any pharmaceutical agent is dependent on its pharmacokinetics.
Undesirable pharmacokinetics leads to faster degradation and clearance of the
pharmaceutical. Elimination of radiolabelled peptides occurs rapidly and mainly by renal
excretion. Rapid excretion of such molecules is advantageous for creating high quality
images with low background activity but unfortunately radiolabelled peptides are often
trapped in the kidneys due to tubular reabsorption.34 The exact mechanism of this process
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is not completely understood but studies suggest that megalin, a multiligand receptor,
plays an important role. Retention in the kidneys not only causes high background noise,
but also delivers high radiation doses. Renal uptake of various radiolabelled peptides has
been reduced by co-administration of cationic amino acids, such as lysine and arginine,
yet these methods come with undesired physical effects such as nausea and
nephrotoxicity.35, 36 Reducing renal uptake has also been achieved by co-administration
of albumin, a megalin substrate.35

1.6 Increasing Receptor Affinity using Multimerization
In 1998, Mammen introduced the theoretical framework for multivalency by stating that
biological species can have multiple simultaneous interactions with ligands or receptors
at any one time.37 Mammen also stated that polyvalency creates stronger interactions
between biological entities.37 Building off this theoretical framework, peptide multimers
were hypothesized as a viable method to increase affinity of any monomeric targeting
entity. Two types of multimers can exist; homomultimers or heteromultimers (Figure
1.6). Homomultimers contain two or more copies of identical targeting entities in one
compound, for example, two copies of RGD tethered together.38 In contrast,
heteromultimers contain two or more different targeting entities in one compound, for
example bombesin and RGD.39

Figure 1.6 Pictorial representation of receptor targeting with homomultimers and
heteromultimers.
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Peptide homodimers, or homomultimers have been well documented to obtain better
binding affinity to biological targets than their monomeric counterparts. The increased
binding affinity is caused by higher local concentration of the targeting entity around the
receptor. More copies of the targeting entity in the immediate surroundings of the
receptor creates a shielding effect that reduces the competition of other endogenous
ligands for the receptor.40 Therefore, after the receptor dissociates from the bound ligand,
it is more likely to bind another copy of the targeting entity in the homodimer or
homomultimer. Extensive studies have been done on multimerization using RGD, an
integrin αvβ3 targeting peptide, by synthesizing a homodimer, homotetramer and
homooctamer of the peptide and integrated radionuclides for in vitro and in vivo
detection. The binding affinity was directly dependent on the number of copies of RGD
in each compound. The highest binding affinity was observed with the homooctamer,
followed by the homotetramer, homodimer and finally the monomer.41
The basis for developing heteromultimers is based on the fact that the cell surfaces of
diseased cells expression many different receptor subtypes. Integrating two targeting
entities into one molecule creates a dual targeting approach. Studies have shown that
heterodimers a bombesin/RGD result in better imaging results when compared to the
monomeric counterparts.42 This phenomenon is caused by an increase in overall receptor
density. When targeting two receptor subtypes, the total available receptor binding sites
increases to the sum of both receptors, where as monomeric targeting entities have less
available binding sites in comparison.40
Multimerization is still a new concept in the area on molecular imaging but initial
research supports the development of homomultimers and heteromultimers to improve
binding affinity of monomeric peptide targeting entities. The design of these peptides can
be difficult without a thorough understanding of the receptor expression. Various
analogues of dimers may be necessary to optimize the molecular space between targeting
entities and the overall three-dimensional conformation of the multimeric compound.43
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1.7 Growth Hormone Secretagogue Receptor-1a and
Ghrelin
Ghrelin is found within the growth hormone secretagogue family that was previously
made up of small synthetic molecules known as growth hormone releasing peptides
(GHRP).44 Secretagogues stimulate the release of hormones, mainly growth hormone,
from the pituitary by activating a G-protein coupled receptor, GHS-R1a. In 1999, Kojima
was the first to discover the endogenous ligand for GHS-R1a that remained unknown for
so long. It was discovered that ghrelin stimulates the release of growth hormone without
affecting any other hormone release. The purified ligand resulted in a 28 amino acid
peptide containing an n-octanoylated serine at residue 3. This ligand was name ghrelin
from the Proto-Indo-European word “ghre” meaning grow.45 The octanoylation observed
in human ghrelin has not been observed previously in peptide modifications, thus this
suggests that this modification happens in a post-translational manner. More
interestingly, there is no structural homology between ghrelin and the synthetic GHSs
previously discovered.

Ghrelin also has no sequence homology to any known

biologically active peptides.45

Figure 1.7 The structure of natural human ghrelin.
Immediately after the discovery of ghrelin, the scientific community became very excited
to understand the critical structural features involved in the ghrelin/GHS-R1a interaction.
A mere four months after the discovery of the ghrelin sequence, the first modified ghrelin
analogues were published. This study began investigating the role of the octanoylated
serine side chain by introducing various other aliphatic and aromatic acids within that
position, the biological importance of the ester linkage at the serine side chain by
replacing this linkage with an amide bond and finally, the minimum human ghrelin
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segment capable of activating GHS-R1a by synthesizing various truncated analogues
(Table 1.2).46
Replacing the octanoylated side chain with hydrophobic acids of comparable size, such
as unsaturated 2,4,6-octatrienoic acid or 11-undecanoic acid, resulted in compounds with
comparable affinity to GHS-R1a. Although incorporation of amino and amido groups
within the side chain resulted in detrimental binding affinity. Replacement of the ester
linkage with an amide linkage had little effect on binding affinity resulted in a more
stable linkage that is not susceptible to esterases or acyl migration. Finally, synthesis of
various truncated ghrelin analogues from ghrelin(1-23) to ghrelin(1-4) were synthesized
and determined that the first 5 N-terminal amino acids are required to not only bind to
GHS-R1a but also to elicit effective activation of GHS-R1a.46 A similar study was
published in 2001 by Mutsumoto and supported the previous findings.47
Table 1.2 Published Modified Ghrelin Analogues.
Ghrelin Analogue

Residue 3

Literature
IC50 (nM)

Ref.

Ghrelin (1-28)

Ser(octanoyl)

0.25

42

Ghrelin(1-28)

Ser(2,4,6-octatrienoic acid)

0.98

42

Ghrelin(1-28)

Ser(11-undecanoic acid)

0.12

42

Ghrelin(1-28)

Ser((CH2)6NH2)

>2000

42

Ghrelin(1-28)

Ser((CH2)2CO-NH-(CH2)2CH3)

1020

42

Ghrelin(1-28)

Dpr(octanoyl)

0.42

42

Ghrelin(1-23)

Ser(octanoyl)

0.16

42

Ghrelin(1-5)

Ser(octanoyl)

55

42

Ghrelin(1-4)

Ser(octanoyl)

889

42

The role of ghrelin is well known to control growth hormone release, metabolism,
appetite and insulin secretion but interestingly, ghrelin has been shown more involvement
in the various stages of cancer such as cell migration, proliferation and apoptosis.48 From
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as early as 2001, the presence of ghrelin production has been noted in many cancer
subtypes such as adrenocortical, breast, colorectal, endocrine pancreatic, endometrial,
gastric, lung, ovarian, pituitary, prostate, renal, and testicular cancers.49-57
Recently, a fluorescent-ghrelin(1-18) analogue was developed and was able to distinguish
prostate cancer from benign hyperplasia in ex vivo prostate tissue (Figure 1.7).58
Additionally, this optical agent was investigated for its ability to image the heart and may
be useful for the imaging of cardiac myopathy, a complication of diabetes.59
Recently, a fluorescent-ghrelin(1-18) analogue was developed and was able to distinguish
prostate cancer from benign hyperplasia in ex vivo prostate tissue (Figure 1.7).52
Additionally, this optical agent was investigated for its ability to image the heart and may
be useful for the imaging of cardiac myopathy, a complication of diabetes.53
Two approaches to the radiolabelling of ghrelin have been explored. The first approach is
the classical method of adding a metal chelator pendant to the peptide analogues at the Cterminus via a lysine residue. In one instance, a DOTA conjugated ghrelin(1-19), which
also contained a diaminopropanoic acid residue in position three, was radiolabelled with
gallium-68 for use as a PET imaging agent and the gallium-69/71 variant was determined
to have an IC50 of 9.1 nM for the GHSR.60 In another instance, a monodentate isocyanide
ligand conjugated ghrelin(1-6) was radiolabelled with technetium-99m and determined to
have an IC50 of 45 nM for GHSR.61 The second approach is an integrated design whereby
the radioisotope is attached as part of a lipophilic side chain, replacing the octanoyl side
chain of native ghrelin. Fluorine-containing side chains, both in the form of an aliphatic
chain and as an aromatic entity, have been reported and the addition of a bulky fluoronapthyl group appears the most promising to date for eventual use as a fluorine-18
labelled ghrelin analogue.62 In addition, a side chain containing a rhenium
cyclopentadienyl tricarbonyl group has also been discovered to have GHSR affinity and
is a unique discovery in that it is a rare example where an organometallic species is a key
recognition element for a peptide-receptor interaction.63
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1.8 Summary
This thesis will document the development of human ghrelin from 28 amino acids, to 19
amino acids and subsequently to 8 amino acids while maintaining affinity to GHS-R1a.
During these truncations, optical dyes and radioisotopes have been integrated into various
positions of the peptide sequence without detriment effects on affinity and enabling these
peptide to visualize GHS-R1a using optical imaging (OI) or PET. Chapter 2 will cover
the first generation ghrelin(1-19) analogue bearing gallium-68 and the evaluation of this
probe in preclinical studies. Chapter 3 will then cover the second generation of ghrelin(18) analogues including an extensive structural activity study followed by optimization of
fluorine-18 for future use in preclinical PET studies. Chapter 4 will investigate the
possible multimerization of a ghrelin(1-8) analogue into ghrelin(1-10) bearing a nearinfrared dye, cyanine-5. Chapter 5 will draw together all aspects of this thesis and
summarize the strengths and weaknesses of ghrelin as an imaging agent capable of
targeting GHS-R1a.
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Chapter 2
Development of a Novel [68Ga]-Ghrelin Analogue for
PET Imaging of GHS-R1a

2

2.1 Introduction
The endogenous ligand for the growth hormone secretagogue receptor (GHS-R) was
discovered in 1999 by Kojima et al. and subsequently named ghrelin.1 This 28 amino
acid natural peptide hormone (Figure 2.1, 2.1) was found to possess a unique posttranslational modification that is not commonly seen in other peptide hormones. Through
the action of ghrelin-O-acyltransferase, natural human ghrelin contains an n-octanoylated
serine at residue 3 that has been found to be essential for its affinity and specificity to
GHS-R. The highest concentration of ghrelin can be found in the stomach and this
peptide is responsible for a diverse area of functions. Its primary role is to regulate
growth hormone (GH) release but it has also shown to have stimulatory effects on
appetite, gastric acid secretion, adiposity and gut motility.2

Figure 2.1 . Amino acid sequence of natural human ghrelin (2.1) and des-acyl ghrelin (2.2) with the
corresponding IC50 for GHS-R1a, as determined.by a competitive binding assay with HEK293 cells stably
transfected with GHS-R1a.

The GHS-R is present in two isoforms, types 1a and 1b. GHS-R1a is a 366 amino acid
polypeptide and G-protein coupled receptor (GPCR) containing seven transmembrane
domains. The third transmembrane domain has been recognized as the ligand-receptor
binding pocket for human ghrelin. On the other hand, GHS-R1b is a 5-transmembrane
receptor that has no binding affinity to human ghrelin and is not known to exhibit any
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biological functions.3 Therefore, GHS-R1a has been labelled the “ghrelin receptor”. The
ghrelin receptor can be found at low concentrations in various tissues such as human
brain, kidney, cardiovascular system and prostate.2, 4
In addition to regulating the growth and differentiation of normal tissues, the GHS-R1a
has been shown to play important roles in proliferation, apoptosis, cell invasion and
migration associated with cancer progression.5-10 More specifically, GHS-R1a has been
found to be differentially expressed in prostate, breast, ovarian, testicular and intestinal
carcinomas when compared to healthy tissue.11-14 By exploiting the specificity of ghrelin
to its endogenous receptor, it has been proposed that ghrelin can be used to locate these
various carcinomas using molecular imaging.15
Within the literature, structure-activity studies of ghrelin have been thoroughly
described.15-20 These studies have revealed that the n-octanoylated serine side chain is
crucial for receptor interaction. The half maximal inhibitory concentration (IC50) of
natural ghrelin (2.1) for GHS-R1a has been reported as low as 0.25 nM and by simply
removing the octanoylated modification, resulting in des-acyl ghrelin (Figure 2.1, 2.2),
the IC50 increases to >10 µM.17 Truncation at the C-terminal end of ghrelin retained
affinity to GHS-R1a, suggesting the N-terminal portion is more important for receptor
interactions. Truncated analogues containing the octanoylated serine such as ghrelin (114) and ghrelin (1-5) resulted in respectable IC50’s of 9.6 nM and 55 nM respectively.17
Lu, et al. synthesized a ghrelin (1-19) analogue bearing a fluorescein dye at lysine19 in
order to optically image human ex vivo prostate tissue ranging from normal, benign
hyperplasia, prostate interneoplasia and cancerous tissue. This modification to ghrelin
resulted in an IC50 of 9.5 nM. Association of fluorescein-ghrelin (1-19) was found to be
4.7 times higher in cancerous prostate tissue than normal and benign hyperplasia.20 This
was the first example highlighting ghrelin’s potential as an imaging probe for prostate
cancer diagnosis and possibly for detection of metastatic disease. The ghrelin (1-19)
skeleton was used again for optical imaging of cardiomyocytes by replacing the
fluorescein dye in the 19th position with a cyanine-5 near-infrared dye. Replacement of
the dye resulted in a slightly lower binding affinity of 25.8 nM but selective targeting of
GHS-R1a is still observed. These findings support the use of ghrelin (1-19) as an
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effective targeting entity in which modifications to position 19 result in minimal effect on
the overall binding affinity.21
Development of ghrelin analogues into PET radiopeptides was first demonstrated with a
therapeutic approach to address obesity, cachexia and anorexia. Ghrelin(1-28) and
ghrelin(1-16) analogues bearing 1,4,7-triazacyclononane, 1-glutaric acid-4,7-acetic acid
(NODAGA) for chelation of gallium-68 were studied in vivo and exhibited good receptor
affinity.22 Ghrelin was also developed as a SPECT radiopeptide by incorporation of
technetium-99m into the ghrelin sequence using various chelating moieties. These
analogues also demonstrated good receptor affinity as well as good biological properties
for further development of ghrelin into diagnostic radiopharmaceuticals.23
These promising results sparked our interest in developing a ghrelin (1-19) analogue
capable of bearing a radionuclide in order to detect prostate carcinomas using a more
sensitive imaging technique. Herein, we describe the synthesis and evaluation of a new
ghrelin (1-19) analogue capable of chelating gallium-68, a PET radionuclide, and
describe preclinical in vivo results using this ghrelin-based PET imaging probe.

2.2 Results and Discussion
2.2.1

Design and Synthesis

Structure-activity studies performed on the ghrelin amino acid sequence suggest that only
the first five N-terminal amino acids are necessary for ghrelin to maintain affinity to
GHS-R1a. As more N-terminal amino acids are added, for example ghrelin (1-14), the
binding affinity improves drastically. Recent literature has shown that ghrelin (1-19) is
able to not only target GHS-R1a, but also tolerate modifications to position 19 without
having a detrimental effect on binding affinity.20, 21 In order to create a ghrelin-based PET
imaging probe, the ghrelin (1-19) analogue was modified so as to possess a tris-tert-butyl
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) chelator at position 19.
A non-radioactive Dpr3(octanoyl),Lys19(DOTA)-ghrelin(1-19) analogue (2.3d) was
synthesized as a reference standard for in vitro assays and radiochemistry. 2.1 was
truncated to contain the first 19 N-terminal amino acids and synthesized using standard
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FMOC solid-phase peptide synthesis techniques. In order to increase in vivo stability and
incorporate a bifunctional chelating moiety, orthogonal protecting groups were used to
modify residue 3 and 19 (Scheme 2.1). Within natural ghrelin, a unique octanoylated
chain is appended to the serine side chain by an ester linkage at Ser-3. To reduce the
occurrence of enzymatic hydrolysis of the ester in vivo, serine was replaced by
diaminopropionic acid (Dpr). This substitution replaces the labile ester linkage with a
more robust amide linkage to the octanoylated chain. Structural studies performed by
Matsumoto et. al. revealed the active core of ghrelin is contained within N-terminal
region of the peptide,41 therefore the incorporation the bifunctional chelator tris-tert-butyl
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) would cause the least
effect if appended to the C-terminal lysine-19 side chain using a pendant design
approach. Upon completion of these modifications, 2.3d was purified by preparative
HPLC. Analytical LC-MS was used to confirm the identity of the products isolated in
>95% purity. 2.3d was then coordinated to naturally occurring gallium-69/71 using
gallium(III) nitrate. The non-radioactive reference standard, [69/71Ga]-2.3d, was used in
further in vitro studies. The identity of the product was also confirmed by analytical LCMS and isolated in >95% purity.

Scheme 2.1 Synthesis of 2.3d.
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2.2.2

In Vitro Analysis

To ensure these modifications have had little detrimental effect on receptor binding, a
competitive binding assay was performed on 2.3d, and [69/71Ga]-2.3d against [125I]ghrelin(1-28). The binding affinity was measured in human embryonic kidney-293 cells
(HEK-293) that were transfected with the GHS-R1a receptor. Varying the concentrations
of each ghrelin analogue in the presence of [125I] human ghrelin resulted in a sigmoidal
binding curve in which the half maximal inhibitory concentration (IC50) values can be
extrapolated

(Figure

log [2.1] (M)

2.2).

As

summarized

in

table

log [2.3d] (M)

2.1,

2.1

has

the

log [69/71Ga-2.3d] (M)

Figure 2.2 Half-maximal inhibitory concentration curves of ghrelin analogues against [125I]-human
ghrelin in HEK293/GHS-R1a cells. 2.1 (A), 2.3d (B), [69/71Ga]-2.3d (C).

best binding affinity to GHS-R1a of 2.05 nM. When comparing the ghrelin(1-19)
analogues, 2.3d and [69/71Ga]-3d, it was observed that [69/71Ga] chelation improves the
binding affinity from 14.9 nM to 5.1 nM. Matsumoto has explored the effect of charge on
the C-terminal end of 2.1. They found that elimination of the C-terminal carboxylic acid
charge by amidation resulted in an eight-fold increase in potency to GHS-R1a.16 This
same trend is observed upon [69/71Ga] chelation to 3d. The carboxylic functionality
charges present in the DOTA becomes neutral upon chelation and in turn, results in a
stronger binding affinity to the GHS-R1a. The synthesized standard, [69/71Ga]-2.3d,
possesses comparable binding affinity to GHS-R1a as the endogenous ligand 1 as well as
the potential to be developed into a PET radiopeptide by complexation to radioactive
gallium-68.
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Table 2.1 IC50 Values for Synthesized Ghrelin Analogues 2.1, 2.3d and [69/71Ga]-2.3d
Ghrelin Analogue IC50 (nM)

2.2.3

2.1

2.05

2.3d

14.9

[69/71Ga]-2.3d

5.67

Radiochemistry

Radiochemistry using gallium-68 (68Ga) has been investigated since the early 1970’s,24
but it wasn’t until 2001 that breakthrough clinical work published on

68

Ga-DOTATOC

for the imaging of neuroendocrine associated disease resulted in an interest in other
clinical applications for gallium-68.25 To date, Gallium-68 has been incorporated into
many peptides, such as bombesin and somatostatin, to visualize various tumour models
using PET.26 Gallium-68 is a preferred isotope for clinical imaging because it has a shortlived half life of 68 minutes and decays 89% by positron emission. This isotope is also
cost-efficient and convenient as it is produced from germanium-68/gallium-68 generators
and does not require an on-site cyclotron. Gallium-68 is eluted as cationic Ga(III) and is
often

associated

with

high

and

reproducible

peptide

labelling

yields.27

Scheme 2.2 Gallium-68 chelation of 2.3d
Radiolabelling of 2.3d was optimized by varying conditions such as the mass of
precursor and buffer concentration, in order to maximize radiochemical yield and specific
activity. In all cases, the reaction mixture was heated at 90°C for 15 minutes before Sep
Pak reverse-phase purification (Scheme 2.2). The various conditions are highlighted in
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Table 2.2. Radiolabelling of 50 µg of 2.3d in 1 M HEPES buffer resulted in the best
decay corrected yield of 96% (d.c) but did not result in a desirable specific activity. In
order to increase the specific activity, the amount of 2.3d was decreased to 25 µg. These
conditions maintained respectable yields of 45-91% (d.c) and increased the specific
activity to more desirable levels, 17.6- 19.0 GBq/µmol. Further reduction of the amount
of 2.3d to 20 µg resulted in similar yields of 54-83% (d.c) and resulted in the highest
obtained specific activity of 10.2-22.8 GBq/µmol. A loss of radiochemical yield and
specific activity was observed when precursor 2.3d was further decreased to 10 µg.
Overall, the best labelling conditions for 2.3d was determined to be 20 µg of precursor in
1M HEPES buffer and these radiolabelling conditions remained standard for all
subsequent studies. The identity of the radiolabelled [68Ga]-2.3d was confirmed by coinjection with [69/71Ga]-2.3d on RP-HPLC resulting in consistent retention times for the
radiolabelled and product standard (Figure 2.3).
Table 2.2 Radiolabelling conditions for [68Ga]-2.3d
Mass of
2.3d (µg)

Buffer

Concentration
(µM)

Decay Corrected
Yield (%)

Specific Activity
(GBq/µmol)

100

0.5 M HEPES

7.83

54

4.51

50

1 M HEPES

3.91

96

3.84-4.28

25

0.5 M HEPES

1.96

45-91

17.6-19.0

20

1M HEPES

1.56

54-83

10.2-22.8

10

1 M HEPES

0.78

17-23

5.39-7.72
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Figure 2.3 RP-HPLC of [69/71Ga]-2.3d and [68Ga]-2.3d

2.2.4

In Vitro Evaluation of 68Ga-Ghrelin (1-19)

The uptake of [68Ga]-2.3d was evaluated in GHS-R1a transfected HEK293 cells. After 60
minutes of incubation of [68Ga]-2.3d with the GHS-R1a expressing cells, each of the cell
pellets (n=6) were placed on a gamma counter and quantified into counts per minute
(cpm). To ensure [68Ga]-2.3d is specifically targeting the same binding site on GHS-R1a,
a blocking study was performed by administering non-radioactive 2.1 prior to [68Ga]2.3d. 2.1 is expected to bind the majority of available GHS-R1a before administration of
[68Ga]-2.3d and result in a decreased cpm as [68Ga]-2.3d is no longer able to associate to
these receptors. As seen in Figure 2.4, HEK293/GHS-R1a cells averaged 24744
counts/second in the presence of [68Ga]-2.3d. When 2.1 is introduced along with the
68

Ga-ghrelin, the activity taken up by the cells drops by 54%. This evidence supports that

2.1 and [68Ga]-2.3d occupy the same binding region on the GHS-R1a.

Figure 2.4 Uptake of [68Ga]-2.3d in HEK293/GHS-R1a cell with and without blocking of GHS-R1a with
2.1.

30

2.2.5

In Vivo Evaluation of 68Ga-Ghrelin (1-19)

To evaluate the effectiveness of the ghrelin-based PET imaging probe, an in vivo
preclinical study was performed with two cell lines, HT1080/GHS-R1a and HT1080.
These chosen cells lines will demonstrate the uptake of the radioligand in a xenograft
overexpressing the receptor of interest compared to a xenograft with normal expression.
[68Ga]-2.3d was studied in vivo in NOD/SCID male mice bearing a HT1080/GHS-R1a
xenograft tumour. As a negative control model, mice bearing HT1080 xenografts were
also studied. Each mouse was administered 7-10 MBq of [68Ga]-2.3d in a saline solution
and immediately underwent a 60 minute µPET dynamic scan. The dynamic scans were
processed into 10 minute intervals to monitor the uptake and accumulation of [68Ga]-2.3d
in the tumour and other organs and tissues. A coronal µPET image (Figure 2.5A) and a
three-dimensional projection (Figure 2.5C) from the small animal PET scanner was taken
at the 30 to 40 minute time interval in the negative control HT1080 mice. The most
notable uptake is visualized in the kidneys (k) and bladder (b). The tumour (t) is present
on the right flank and accumulated a small amount of residual radioactivity. The residual
radioactivity can be attributed to circulation of the [68Ga]-2.3d and its metabolites
through the highly vascularized tumour rather than association to receptors in the
HT1080 cell line. A coronal µPET image (Figure 2.5B) and a three-dimensional
projection (Figure 2.5D) from the small animal µPET scanner was also taken at the 30 to
40 minute time interval in the positive HT1080/GHS-R1a mice. Similar to the control,
there is high uptake in the kidneys (k) and the bladder (b). More radioactivity has now
been localized and retained in the tumour (t) on the left flank. The retention of the probe
is believed to be due to the active binding of [68Ga]-2.3d to GHS-R1a in the xenograft.
The high localization of radioactivity to the kidneys is a common trait seen in
radiolabelled peptides as through tubular reabsorption. Radiolabelled peptides often
become trapped causing undesirable effects such as nephrotoxicity and this can be
combated by reducing the presence of charged side chains within the peptide or
administering a cationic amino acid prior to injection of the radiolabelled peptide.28

31

Figure 2.5 A 60 minute dynamic uPET scan showing uptake of [68Ga]-2.3d from 30-40 minutes in
HT1080 and HT1080/GHS-R1a xenografts. (A) HT1080 – coronal. (B) HT1080/GHS-R1a – coronal, (C)
HT1080 – 3D projection and (D) HT1080/GHS-R1a – 3D projection.

To more accurately compare the uptake of [68Ga]-2.3d in both tumour models, standard
uptake values (SUV) were calculated by designating volumes of interest (VOI) for each
xenografts over the 60 minute scan using AsiPro software. The SUVs were calculated
using Equation 2.1 (supplemental materials) and graphed in Figure 2.6. The SUV for
HT1080/GHS-R1a xenograft mice is approximately 5 times greater than the HT1080
xenografts. These results show [68Ga]-2.3d is selective to xenografts that contain GHSR1a receptors compared to those with limited receptor expression, such as the control
HT1080 cell line.
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Figure 2.6 Graphical representation of SUVs for [68Ga]-2.3d in HT1080/GHS-R1a and HT1080
xenographs over 60 minutes.

2.2.6

Conclusions

The objective of this work was to develop a ghrelin-based PET imaging probe capable of
targeting the endogenous GHS-R1a with comparable affinities to the natural ligand.
Truncating ghrelin (1) to the first 19 N-terminal amino acids and modifying positions 3
and 19 not only increased the stability and introduced a bifunctional chelator, these
modifications provided a high affinity ligand to GHS-R1a. IC50 studies determined that
the 69/71Ga-ghrelin complex had an improved IC50 value compared to the non-coordinated
2.3d. When evaluated in vivo, [68Ga]-2.3d shows localization in HT1080/GHS-R1a
xenografts within the first 30 minutes of circulation that is not present in the HT1080
negative control. Examining the SUV values over 60 minutes in each xenograft results in
approximately 5 times greater uptake [68Ga]-2.3d in the presence of GHS-R1a. The high
localization of [68Ga]-2.3d in the kidneys raises a concern for nephrotoxicity and suggests
the need for further optimization of this analogue. Smaller ghrelin analogues are currently
being developed in hopes of decreasing kidney retention and optimizing pharmacokinetic
behaviour.
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2.3 Experimental
2.3.1

Materials and Methods

All common solvents were purchased from Fisher Scientific. All protected amino acids,
coupling reagents and resins were purchased from Novabiochem, Peptides International
and Chem-Impex and were used without further purification unless otherwise stated. All
reagents were obtained from Sigma-Aldrich with the exception of gallium (III) nitrate
hydrate that was obtained from Strem Chemicals, HEPES free acid that was obtained
from AMRESCO and tris-t-butyl DOTA that was obtained from CheMatech. RP-tC18
Sep-Pak SPE cartridges were purchased from Waters. [125I]-ghrelin was purchased from
Perkin Elmer. The germanium/gallium generator and all its corresponding parts were
purchased from Eckert and Ziegler Strahlen- und Medizintechnik AG. For analytical
HPLC-MS, a Sunfire RP-C18 4.6 x 250 mm, 5 µm column was used. For preparative
HPLC-MS work, a Sunfire RP-C18 19 x 150 mm, 5 µm column was used. A gradient
solvent system was used containing 0.1% TFA in acetonitrile (solvent A) and 0.1% TFA
in water (solvent B). For analytical UHPLC-MS, studies were performed on a Waters,
Inc. Acquity UHPLC H-Class system, combined with a Xevo QTof mass spectrometer
(ESI+, cone voltage = 30 V). For analytical UHPLC-MS studies, a Waters Acquity
UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column was used with a gradient solvent system
consisting of 0.1% formic acid in acetonitrile (solvent C) and 0.1% formic acid in water
(solvent D). Analytical radio-RP-HPLC (SunfireTM RP-C18 column 4.6 x 150 mm, 5 µm)
was performed on a Waters 1525 Binary HPLC pump containing a Waters 2487 dual λ
absorbance detector, Waters in-line degasser, a gamma detector and Breeze software
(version 3.30).

2.3.2

Synthesis of 2.3d

Peptide synthesis was carried out manually using FMOC-based solid-phase peptide
chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA resin
(0.51 mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF),
followed by FMOC deprotection using 2 mL of 20% piperidine in N,Ndimethylformamide (DMF) for two cycles (10 minutes, 5 minutes). Amino acids were

34

preactivated by combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq.
of N,N-diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the
resin and coupled for 30 minutes and repeated again for 60 minutes. These cycles were
repeated until all 19 N-terminal amino acids were coupled to the resin.
Methyl trityl deprotection was carried out by mixing the resin with 2 mL of 2%
trifluoroacetic acid (TFA) + 5% triisopropylsilane (TIS) in dichloromethane (DCM)
solution for 2 minutes and repeating for 8 cycles, or until the yellow colour no longer
persisted. To neutralize residual TFA, the resin was treated with 200 µL of DIPEA in
DMF for 5 minutes. Octanoic acid was coupled to the resulting free amine using 3 eq.
octanoic acid, 3 eq. HCTU and 3 eq. of DIPEA in DMF. The mixture was left to couple
overnight.
Allyloxycarbonyl deprotection was performed under inert atmospheric N2 conditions.
DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2 eq. of
phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by 0.045 eq.
of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide vessel was
removed from inert conditions and allowed to react for 30 minutes. The resulting free
amine was coupled to the chelator using 2 eq. of tris-t-butyl DOTA, 2 eq. of HCTU and 6
eq. of DIPEA in DMF. The reaction mixture was left to couple overnight.
Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of
95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5 hours. The
cleaved peptide was precipitated from solution using ice-cold tert-butyl methyl ether
(TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude peptide pellet. The
supernatant was decanted and the resulting peptide pellet was dissolved in 20%
acetonitrile in water, frozen at -78 °C and lyophilized to a white crude powder.
Purification was performed using preparative HPLC-MS on a gradient of 20% to 60%
solvent A in B over 10 minutes. Purity of the resulting peptide was analyzed using
analytical UHPLC on a gradient of 10% to 60% solvent C in D over 4 minutes. Pure
peptide was isolate in a 21% yield. HRMS (ESI+): m/z calculated for C118H195N38O37,
[M+2H]2+ = 1370.2927, observed [M+2H]2+= 1370.1941
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Synthesis of [69/71Ga]-2.3d

2.3.3

Purified 2.3d (5 mg) was dissolved in 1 mL of distilled water in a 5 mL pear-shaped
round bottom flask. Ga(NO3)3 (20 eq., 8 mg) was added to the flask and stirred at 60 °C
for one hour. The reaction mixture was diluted with 3 mL of distilled water and loaded
onto a tC18 Sep Pak SPE cartridge. The cartridge was rinsed with 2 mL of distilled water
to remove excess gallium, and [69/71Ga]-2.3d was eluted from the cartridge with 3 mL of
50% ACN/H2O (3 x 1 mL aliquots). Each aliquot was analyzed by RP-UHPLC to
confirm the identity and purity of [69/71Ga]-2.3d. Pure [69/71Ga]-2.3d was isolated in 86%
yield. HRMS (ESI+): m/z calculated for C118H193N38O3769Ga, [M+2H]2+ = 1403.6979,
observed [M+2H]2+= 1403.8301.

2.3.4

Radiochemistry

A sterile 10 mL reaction vial was loaded with 2.3d (10 – 100 µg) in HEPES buffer (0.5 –
1 M, pH 4); all conditions can be found in Table 1. Fresh radioactive 68Ga3+ was eluted
from a 68Ge/68Ga generator using 0.1 M hydrochloric acid (HCl) and trapped on a Strata
X C cation exchange column. The column was eluted with 0.1 M HCl in acetone to
transfer

68

Ga3+ to the reaction vial. In all cases, the solution was heated to 90 oC for 15

minutes followed by dilution with 3 mL of milliQ water. The diluted mixture was loaded
onto a precondition tC18 sep pak SPE cartridge to remove unchelated

68

Ga3+. The

radiolabelled peptide was eluted with 1 mL of ethanol into a sterile product vial. Specific
activities were calculated by assuming all unlabelled 2.3d remains present in the product
vial. The optimal manual labelling conditions were obtained with 20 µg of 2.3d in 1 M
HEPES buffer. The radiolabelled peptide was obtained in a 54-83% decay corrected yield
and specific activity of 10.2 – 22.8 GBq/µmol. Radiochemical purity was assessed using
RP-HPLC coupled to a gamma detector, prior to use in in vitro and in vivo assays.

2.3.5

Competitive Binding Assays (IC50)

The affinity for GHS-R1a was determined using a radioligand binding assay. Assays
were performed using GHS-R1a transfected HEK293 cells as receptor source and human
[125I]-ghrelin(1-28) (PerkinElmer Inc.) as radioligand. Human ghrelin(1-28) was used as
reference to ensure the validity of the results. [69/71Ga]-3d and 3d (at concentrations of 10-
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M, 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per

assay tube) were mixed in binding buffer (25 mM HEPES, 5 mM magnesium chloride, 1
mM calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH 7.4). A suspension of
membrane from HEK293S cells (50,000 cells per assay tube) was added to the assay tube
containing test peptides and [125I]-ghrelin(1-28). The resulting suspension was incubated
for 20 minutes under shaking (550 rpm). Unbound [125I]-ghrelin was removed and the
amount of [125I]-ghrelin bound to the membranes was measured on a gamma counter.
IC50 values were determined by nonlinear regression analysis to fit a 4 parameter dose
response curve using GraphPad Prism (Version 6.0c) and summarized in Table 2.2. All
binding assays were performed in triplicate.29

2.3.6

In Vitro Evaluation of [68Ga]-2.3d

[68Ga]-2.3d was incubated with 1 million HEK293/GHS-R1a cells (n=6) in 1 mL of
binding buffer (25 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 2.5 mM EDTA, 0.4% BSA)
for 1 hour at 37 oC. After 1 hour, the cells were pelleted, washed thoroughly with binding
buffer (3 x 1 mL) and the radioactivity was measured using a gamma counter. Blocking
studies were performed by administering 20 equivalents (20 µg) of human ghrelin to 1
million HEK293/GHS-R1a cells (n=6) in 1 mL of binding buffer and immediately before
administering [68Ga]-2.3d. The mixture was incubated for 1 hour at 37oC, pelleted,
washed and the radioactivity measured using a gamma counter. Measurements were
recorded in counts/second and used to calculate the mean and standard deviation.

2.3.7

In Vivo Evaluation

In vivo imaging studies were carried out in two cell lines, HT1080/GHS-R1a (receptor
positive) and HT1080 (natural expression). HT1080 xenografts were grown on the right
upper flank of male NOD/SCID mice by injecting two million cells of HT1080 (n=1)
while HT1080/GHS-R1a xenografts were grown on the left flank by injecting two million
cells of HT1080/GHS-R1a (n=1). Tumours of approximately 1 centimeter in diameter,
were present two weeks post injection. Each mouse was administered 7-10 MBq of
[68Ga]-2.3d via tail vein injection. A 60-minute dynamic small animal PET scan was
performed on both cell lines (Figure 5A-D).
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µPET scans were reconstructed using CarimasTM software developed at the Turku PET
Centre (Turku, Finland).30 To reduce variability due to mouse size and injected dose, all
radiotracer accumulation was quantified with respect to standard uptake values (SUV)
and normalized to the kidney uptake, therefore µPET scans are represented as SUV ratio
(SUVr) values. SUVs were determined using AsiPro software (Concorde Microsystems,
Knoxville, Tenn, USA). Volumes of interest (VOI) were contoured by hand resulting in
3D reconstruction of the tumour. The image derived radioactivity concentration (Bq/cc)
was determined for each VOI based on the injected dose. Standard uptake values (SUV)
are then calculated using equation 2.1 (supplemental materials) where SUV(t) is the
standard uptake value at time t, C(t) is the imaged derived radioactivity concentration in
Bq/cc, ID(t) is the injected dose at time t, and W is the weight of the mouse in grams.
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Chapter 3

3

Structural-Activity Study of Ghrelin(1-8) Resulting in
Potent Fluorine-bearing Ligands for GHS-R1a
3.1 Introduction
The recent advances in the field of molecular imaging have vastly influenced disease
monitoring, staging and diagnosis. Molecular imaging techniques, such as optical
imaging (OI), positron emission tomography (PET) and single-photon emission
computed tomography (SPECT), have been used to develop a better understanding of
specific molecular events occurring within a disease state.1 The field of oncology has
greatly benefitted from developments in molecular imaging. Classical methods of cancer
diagnosis, such as histology, are slowly being replaced by new non-invasive methods
developed through molecular imaging. One approach to developing these methodologies
is identifying molecular receptors involved in the proliferation, migration and cell
invasion processes associated with cancer progression and using them as a marker for the
disease.2 For example, somatostatin receptors are highly expressed on the cell surface of
specific neoplastic tissues. Considerable research effort has been dedicated to targeting
this receptor using its endogenous peptide ligand, somatostatin. Unfortunately, the
naturally occurring 28-mer and 14-mer somatostatin ligands are known to have poor in
vivo stability. In an effort to improve metabolic stability, collections of modified
somatostatin analogues were developed by structure-activity studies. From these
analogues, a cyclic octapeptide, known as octreotide, was found to be more stable than
somatostatin. Using a pendant design approach, chelating moieties were appended to the
cyclic peptide to incorporate various radiometals such as

64

Cu,

68

Ga and

111

In. These

analogues are now capable of detecting neuroendocrine tumours using scintigraphy and
have been evaluated in preclinical and clinical studies.3-5 This approach to designing
stable, high affinity peptide ligands for tumour receptors has led to many new peptide
ligands based off of integrin, gastrin-releasing peptide, cholestokinin and alphamelanocyte stimulating hormone and continues to be an area of focus for designing new
receptor-binding peptide ligands.
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An exciting new receptor holding potential relevance to certain cancers is the
growth-hormone secretagogue receptor (GHS-R). GHS-R has been detected in two
isoforms. GHS-R1a is a G-protein coupled receptor known to induce growth-hormone
release, as well as various other functions, mediated by its endogenous ligand ghrelin.
GHS-R1b is a truncated 5-transmembrane receptor found to be functionally inactive and
possessing no known endogenous ligands.6 Initially, it was proposed that GHS-R1a was
solely expressed in the pituitary and hypothalamus but more intensive studies show that
although GHS-R1a is predominately expressed in the pituitary, it is also present in low
levels in peripheral tissues including the thyroid, pancreas, spleen, myocardium and
adrenal gland.6 More importantly, GHS-R1a is differentially expressed in healthy human
tissues and several tumour types such as prostate, breast, testicular and ovarian
carcinomas.7-11

Figure 3.1 Preproghrelin undergoes proteolytic cleavage resulting in desacyl ghrelin (3.1) which
undergoes acylation by ghrelin O-acyl transferase resulting in ghrelin(1-28) (3.2).

The endogenous ligand for GHS-R1a is ghrelin (3.2), a 28 amino acid peptide
hormone (GSS(octanoyl)FLSPEHQRVQQRKESKKPPAKLQPR) that possesses a
unique octanoyl chain on the serine side chain at position 3. Human ghrelin originates
from preproghrelin, a 177-amino acid protein that undergoes proteolytic cleavage to a 28
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amino acid peptide known as desacyl ghrelin (3.1). Compound 3.1 possesses the same
amino acid sequence as 3.2, but lacks the octanoyl chain present at position 3.12 Without
the octanoyl chain, 3.1 has virtually no affinity (IC50 > 10000 nM) affinity to GHS-R1a
as determined by a competitive binding assay. 3.1 then undergoes acylation by the
ghrelin O-acyl transferase (GOAT) to yield the unique octanoyl modification. It is this
unique modification that significantly increases the affinity to GHS-R1a to 2.05 nM
(Figure 3.1).13
Ghrelin provides a high affinity template as a starting point to further develop into a
radiopeptide. Like many other peptides, ghrelin lacks in vivo stability and requires
modifications such as truncation and amino acid substitution in order to resist in vivo
degradation and maintain affinity to GHS-R1a. Much like somatostatin, a methodical
structural activity study of ghrelin will help to better understand the role each amino acid
plays in the interaction with GHS-R1a. We propose that truncation of ghrelin to the first
eight N-terminal amino acids will result in high affinity ghrelin analogues by selectively
modifying amino acids important for receptor interaction. We will also incorporate a
radionuclide into the ghrelin scaffold that is integral for receptor interaction. This
requires the development of a new fluorine-18 prosthetic group and results in a high
affinity ghrelin(1-8) analogue capable of targeting GHS-R1a.

3.2 Results and Discussion
3.2.1

Design of Ghrelin Analogues for Positron Emission
Tomography (PET)

A significant quantity of literature has focused on describing studies where the ghrelin(128) structure is modified in order to determine the portions necessary for activity, the role
of the octanoyl chain, as well as determining the shortest peptide fragment to activate the
receptor.14,

15

Matsumoto et al. determined that the C-terminal region of the peptide,

ghrelin(16-28), has no affinity to the GHS-R1a. The N-terminal region of the peptide was
then investigated to determine how many amino acids must be maintained to ensure
affinity to GHS-R1a. When truncated to the first 14 N-terminal amino acids, ghrelin(114), affinity to GHS-R1a remained respectable with an IC50 of 9.6 nM. As further
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truncation occurred, there was an increasing loss of affinity for the receptor. For example,
ghrelin(1-10) has an IC50 of 19 nM while ghrelin(1-4) has an IC50 of 480 nM. When
ghrelin was truncated to less than 4 amino acids, all affinity to the receptor was lost
suggesting the first 4 amino acids play an integral role in the affinity to GHS-R1a.14
When VanCraenenbroeck et al. studied ghrelin(1-14) analogues, they discovered that
placing an alanine or tyrosine in position 8 resulted in the most potent ghrelin(1-14)
analogues. These findings suggest that the negatively charged glutamic acid found in
natural ghrelin is not the optimal choice for this position. Synthesizing several ghrelin(18) analogues that replace glutamic acid with various hydrophobic or polar-uncharged side
chains could result in an optimal amino acid capable of targeting GHS-R1a with equal or
greater affinity then ghrelin(1-28).16 Modifications were made to positions 3 and 8 while
the other amino acids remained the same as the natural ghrelin sequence. At position 3,
serine was replaced with the unnatural amino acid diaminopropionic acid (Dpr) to replace
the ester linkage with a more synthetically facile and stable amide linkage.17, 18 Octanoic
acid was added to the side chain of Dpr using standard coupling conditions. Position 8
was modified to contain all the hydrophobic aromatic side chain amino acids;
phenylalanine (F), tyrosine (Y) and tryptophan (W), and compared to the natural
sequence bearing glutamic acid (E). The binding affinity to GHS-R1a was determined
using a previously reported competitive binding assay.18 As summarized in Table 3.1, E
as residue 8 resulted in an IC50 of 200 nM but replacing this residue with hydrophobic
aromatic side chain greatly increased the binding affinity. W and Y were less effective
substitutions resulting in 86.3 nM (3.3c) and 65.0 nM (3.3a), respectively, while the
binding affinity substantially increased with F to 6.67 nM (3.3b). Position 8 was also
substituted with amino acids bearing polar-uncharged side chains; serine (S), asparagine
(N), glutamine (Q) and threonine (T). These substitutions lead to higher affinity
analogues than the hydrophobic aromatic side chains. The best analogue 3.3f (Figure
3.2A), with T in the 8th position, had a 3.26 nM IC50, while N (3.3d), S (3.3g) and Q
(3.3e) were less effective with 31.9 nM, 28.8 nM and 21.7 nM respectively.
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Table 3.1 : Substitution of residue 8 with various natural and unnatural amino acids and the resulting
IC50 (nM) for GHS-R1a.

Figure 3.2 IC50 curves of lead analogues 3.3f (A), 3.5b (B) and 3.6a (C) after modifications were made
to positions 8, 1 and 4, respectively.

One drawback to using peptides as targeting entities is the in vivo stability of peptides.
For example, natural human ghrelin(1-28) has a biological half-life on the scale of 9-12
minutes.19 In order to increase the stability of the developed ghrelin(1-8) analogues,
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bioisosteres can be added to reduce degradation by endopeptidases and exopeptidases.
Bioisosteres are chemical groups that possess similar physical and chemical properties to
another chemical compound as well as elicit similar biological properties.20 Bioisosteres
of F and T, the two lead modifications to position 8, were incorporated into the peptide
sequence in hopes of maintaining the affinity to GHS-R1a of the natural amino acid as
well as increasing the overall stability of the peptide. As summarized in Table 3.1, two
bioisosteres of T were introduced, D-threonine (3.3h) and β-homo-threonine (3.3i). These
modifications had a negative effect on binding affinity by increasing the IC50 to 66.0 nM
and 45.0 nM, respectively. 2-Naphthylalanine (2-Nal, 3.3j) was also introduced as a nonclassical bioisostere for F and also had a negative effect on IC50, increasing it 24.8 nM.
Overall, two amino acids were found to more effectively increase binding affinity than E.
These two amino acids are F (3.3b) and T (3.3f).
Bednarek, et al. investigated the importance of the octanoyl chain by evaluating several
analogues where serine-3 was acylated with different aliphatic and aromatic acids. When
serine-3 is acylated with large aliphatic groups, such as 11-undecanoic acid, the affinity
to GHS-R1a is as effective as natural human ghrelin. Yet, when small, less hydrophobic
acids are present, such as formic acid, all affinity to GHS-R1a is lost. This investigation
demonstrates that ghrelin is able to tolerate large lipophilic groups at position 3 and
possibly provides the opportunity to create a short ghrelin analogue with a radioisotope
integrated into the side chain at position 3.13 To test this hypothesis, Rosita et. al.
integrated lipophilic groups bearing fluorine-19 and rhenium-185/187 in position 3 of
ghrelin(1-14)-amide to investigate the potential as PET imaging agents for GHS-R1a.
The most promising fluorine-19 group contained a 12-carbon chain, the IC50 was 27.9 nM
and the most promising rhenium-185/187 contained a cyclopentadienyl-rhenium complex
after a 3-carbon chain that resulted in a 35 nM affinity. These analogues were not further
developed into PET imaging agents but acted as inspiration for further development of
ghrelin(1-8) analogues that require a radioisotope for association to the native receptor.21
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Table 3.2 Substitution of Dpr side chain with various fluorine-bearing aromatic prosthetic groups and the
resulting IC50 (nM) for GHS-R1a.

Since it was demonstrated that large lipophilic groups were tolerated in position 3, we
chose to integrate a well-known fluorine-18 prosthetic group, 4-fluorobenzoic acid (4FBA), at the end of the Dpr side chain. 4-[18F]FBA has been used to radiolabel various
peptides such as RGD and bombesin, and has well developed radiochemical
procedures.22, 23 Shown in Table 3.2, integration of 4-FBA (3.4a) onto residue 3 resulted
in a less than optimal IC50, of 65 nM. In order to increase the lipophilicity of the
prosthetic group, another aromatic ring was added by introducing 6-fluoronaphthoic acid
(6-FNA, 3.4b) and 4’-fluoro-[1,1’-biphenyl]-4-carboxylic acid (4’-FBC, 3.4c) using
standard coupling conditions. The increased lipophilicity had a positive effect on binding
affinity to 9.9 nM and 3.5 nM, respectively, and led us to develop a new fluorine-18
prosthetic group. Unfortunately nucleophilic aromatic substitution with the biphenyl
scaffold proved to be low yielding and therefore, 6-FNA was further developed into a
prosthetic group rather than 4’-FBC.
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Table 3.3 Substitution of residue 1 and 4 with various unnatural amino acids and the resulting IC50 (nM)
for GHS-R1a.

Following the choice of a suitable prosthetic group for position 3, further modifications
were made to the N-terminal residue 1 and residue 4 in hopes of further increasing in vivo
stability and GHS-R1a affinity using more unnatural amino acids. The N-terminal glycine
was replaced with one of three unnatural amino acids; aminoisobutyric acid (Aib),
isonipecotic acid (Inp) or sarcosine (Sar). The secondary amine found in Sar (3.5c) had a
large negative effect on IC50 causing it to rise to 262 nM, while the secondary amine
found in Inp (3.5b, Figure 3.2B) had the opposite effect decreasing it to a desirable IC50
of 9.64 nM. Aib, a primary amine, also had a positive effect on IC50 decreasing it to 9.26
nM (Table 3.3). When choosing the most suitable candidate for residue 1, Inp was
chosen in order to reduce the presence of primary amines during the radiochemical
prosthetic group labelling. VanCraenenbroeck performed an alanine scan on ghrelin(114) and determined that the Phe present at residue 4 was integral for interaction with
GHS-R1a. Replacement of this residue with alanine or tyrosine caused a decrease in
binding affinity.16 Therefore, we hypothesized that replacing Phe with a larger, more
lipophilic side chain may create a stronger interaction between the ligand and receptor.
Substitution of Phe with Nal-1 and Nal-2 had varied success (Table 3.3). Nal-1 was able
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to increase the affinity to GHS-R1a greatly from 65 nM (3.4a) to 4.12 nM (3.6a, Figure
3.2C) while Nal-2 had a detrimental effect result in a large loss of affinity.
A thorough investigation into the amino acid sequence of ghrelin(1-8)-amide has led to
many analogues with binding affinities comparable to ghrelin(1-28). Combining the most
successful substitutions has led to a lead peptide analogue (Figure 3.3) to be further
developed into a fluorine-18 PET imaging agent. The best substitutions were Inp, Nal-1
and Thr in positions 1, 4 and 8, respectively and coupling 4-FNA to the side chain of Dpr
at position 3. Compound 3.7 resulted in the best IC50 of all ghrelin analogues at 0.16 nM
and supported the further development of this peptide into a PET radiopeptide by
incorporating fluorine-18.

Figure 3.3 Amino acid structure (A) and IC50 curve (B) of the the ghrelin (1-8) analogue bearing lead
modifications to all positions 1, 3, 4 and 8.

3.2.2

Synthesis of Prosthetic Groups and Standards

The synthesis of the new prosthetic group precursor 3.11 is outlined in scheme 3.1.
Prosthetic group precursor 3.11 was obtained in good yield following a 3-step synthesis.
The commercially available starting material, 6-amino-2-naphthoic acid (3.8), was
dissolved in ethanol and acidified with sulfuric acid (pH 4) to produce 6-amino-2-ethyl
naphthoate (3.9). Following purification by flash column chromatography, 3.9 was
dimethylated by an Eschweiler-Clarke reaction using sodium cyanoborohydride and
formaldehyde to produce 3.10. The final synthetic step requires methylation of the
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dimethylamine with the strong methylating agent, methyl trifluoromethanesulfonate
(MeOTf). The resulting 6-trimethylamino-2-ethylnaphthoate trifluoromethanesulfonate
(3.11) was obtained as a pure white powder after precipitation and recrystallization. The
identity of the product was confirmed by proton and carbon NMR spectroscopy as well as
mass spectrometry. This prosthetic group was designed to undergo nucleophilic aromatic
substitution in the presence nucleophilic fluorine. The electron withdrawing nature of the
ethyl ester at carbon-2 activates the ring for nucleophilic attack by fluorine at carbon-6.
The trimethylammonium acts as a better quality leaving group resulting in a substitution
with fluorine. Therefore, employment of the standard radiofluorination protocols using
potassium carbonate and kryptofix 2.2.2 was expected to be suitable for radiolabelling of
this prosthetic group.

Scheme 3.1 Synthesis of 6-trimethylamino-2-ethyl-naphthoate triflate (3.11)
Most fluorine-18-labelled prosthetic groups reported in the literature are designed as
activated esters for facile acylation to peptide targeting entities. The most common
activated ester reported is the N-hydroxysuccinimide ester used for 4-[18F]-fluorobenzoic
acid to result in N-succinimidyl-4-[18F]-fluorobenzoate. Unfortunately, acylation of our
lead peptide analogue with an N-hydroxysuccinimide ester of 6-fluoro-2-napthoic acid
resulted in degradation of the active ester due to harsh conditions. The sluggish and low
yielding reactions therefore led us to seek out a different active ester. Pentafluorophenyl
(PFP) esters are becoming recognized for the increased stability and reaction rate when
compared to NHS esters.24, 25
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Scheme 3.2 Synthesis of the non-radioactive standard 6-fluoro-2-pentafluorophenyl naphthoate (PFPN,
3.13)

A non-radioactive 6-fluoro-2-pentafluorophenylnaphthoate ([19F]-PFPN) standard was
synthesized using 6-fluoro-2-napthoic acid, pentafluorophenol and DMAP. The desired
activated ester was purified by flash column chromatography in an 86% yield and
verified by 1H NMR,

13

C NMR spectroscopy and high-resolution mass spectrometry

(HRMS). A peptide precursor of 3.7 was synthesized to possess a free amine at the Dpr
residue in position 3. This peptide was synthesized on Rink Amide MBHA resin with all
amino acids bearing standard protecting groups. Upon cleavage from the resin using
strong acid, all the protecting groups were removed leaving one primary amine at
position 3 and a secondary amine on the N-terminus. This peptide precursor (3.17) is
capable to coupling to PFPN in the presence of a weak base producing the desired
radiolabelled ghrelin(1-8) peptide.

3.2.3

Radiochemistry

Full synthesis of [18F]-3.7 was carried out in 4 synthetic steps summarized in scheme 3.3.
The first two steps were carried out on the automated Tracer Lab FXFN synthesis box.
Shown in Figure 4, the configuration of the synthesis box was slightly modified to
accommodate the first two synthetic steps. Valve 14 (V14) was directly attached to a
product output line to bypass the rest of the synthesis system and transfer the crude
reaction material from the reaction vial to a product vial outside the synthesis box for
further manipulation.
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Scheme 3.3 The radiosynthetic pathway for the synthesis of [18F]-PFPN by automated and manual
synthesis.

Figure 3.4 The modified schematic of Tracer Lab FXFN for the synthesis of 6-[18F]-fluoro-2-naphthoic
acid (3.15).

The TracerLab FXFN was prepared for synthesis by filling vial 1 with a solution of 2 mg
potassium carbonate and 7 mg of kryptofix 2.2.2 in 200 µL of milliQ water and 800 µL of
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acetonitrile (ACN). Vials 2 and 3 were filled with 1 mL of dry ACN each, used to
azeotropically dry the nucleophilic fluoride-18. 2 mg of precursor 3.11 was added to vial
4 in 750 µL of dry dimethylsulfoxide (DMSO). Finally, vial 5 contained 20 µL of 1M
tetramethylammonium hydroxide (in water, TMAH) in 1 mL of ACN for deprotection of
the ethyl ester.
Fluorine-18 was delivered to the synthesis box in H2[18O] and trapped on a Waters QMA
Carbonate Sep Pak. The activity was then eluted into the reaction vial by the solution in
vial 1. The solution was then azeotropically dried for 5 minutes at 75°C with the solution
in vial 2 and repeated for vial 3. Following drying, precursor 3.11 was introduced to the
reaction vial from vial 4 and allowed to react at 110°C for 10 minutes resulting in 6-[18F]2-ethylnaphoate (3.14). 1M TMAH (20 µL) in 1 mL of ACN was then added to the
reaction mixture from vial 5 and heated to 90 °C for 10 minutes. After cooling the
reaction mixture to 40 °C, the reaction crude was then transferred from the reaction vial
to a product vial containing 7 mL of milliQ water and 0.1% TFA in the side chamber via
valve 14. The following steps were carried out manually. The diluted reaction crude was
loaded onto a tC18 Sep Pak to remove any unreacted nucleophilic fluorine-18. 6-[18F]-4Naphthoic acid (3.15) was eluted from the tC18 Sep Pak with 1 mL of acetonitrile into a
reaction vial containing 20 mg of pentafluorophenol, 10 mg 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) and 1 mg 4-dimethylaminopyridine (DMAP).
The reaction mixture was allowed to sit at room temperature for 5 minutes at which time
1 mL of milliQ water was added to the crude reaction mixture. The diluted mixture is
then purified by semi-preparative HPLC (55 – 95% acetonitrile in water) to collect the
pure 6-[18F]-2-pentafluorophenylnaphthoate in 6.5% decay corrected yield. The purified
3.16 was redissolved in 1 mL of acetonitrile containing 1.5 mg of peptide precursor
(3.17) (Scheme 3.4). After administration of 30 µL of diisopropylethylamine (DIPEA),
the reaction mixture was warmed at 40 °C for 20 minutes before being diluted with 500
µL milliQ water and purified by semi-preparative HPLC (20 – 80% acetonitrile in water).
HPLC purified [18F]3.7 was collected at 5 minutes in a 3.1% decay corrected yield. The
identity of 3.18 was confirmed by co-injection with the non-radioactive standard 3.7
(Figure 3.5).
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Scheme 3.4 Coupling of [18F]-PFPN to the lead ghrelin(1-8) analogue resulting in [18F]-3.7.

Figure 3.5 Overlaid C18 reverse-phase HPLC chromatograms of [19F]-3.7 (AU) and [18F]-3.7 (mV).

3.2.4

Conclusions

Ghrelin has shown it is capable of distinguishing between cancerous and benign prostate
tissue that has shown to be a difficult task with other clinical PET imaging agents, such
as [18F]-fluorodeoxyglucose. This emphasizes the need for new ghrelin-based PET
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probes. The natural ghrelin(1-8) sequence was methodically altered to increase the
affinity to GHS-R1a from 200 nM to 0.16 nM. Modifications made at positions 1, 3, 4
and 8 resulted in various analogues with IC50 values equal or better than ghrelin(1-28).
Compiling all the lead modifications into one peptide analogue resulted in [Inp1, Dpr3(6fluoro-2-naphthoate), 1-Nal4, Thr8] ghrelin(1-8) which possessed a fluorine for further
development into a PET radiopeptide. 3.7 resulted in a 1250-fold increase of affinity to
GHS-R1a than 3.3 based off their IC50 values. In order to incorporate fluorine-18, a new
prosthetic group, [18F]-PFPN, was developed using a combination of automated and
manual synthesis with a TracerLab FXFN synthesis box. Coupling of [18F]-PFPN to the
lead peptide analogue with a free amine at residue 3 resulted in the first fluorine-18
labelled, high affinity ghrelin (1-8) analogue for GHS-R1a in an overall 3.1%
radiochemical yield (d.c.). Therefore, this reports the successful radiolabelling of the first
fluorine-18 labelled ghrelin(1-8) analogue. This is not only the highest affinity ghrelin
analogue reported in the literature, it is also the shortest ghrelin analogue capable of
binding GHS-R1a with better affinity than ghrelin(1-28).
Preclinical evaluation of this PET probe is currently underway in prostate cancer models
although [18F]-3.7 can be a valuable tool for visualizing various tissues and disease states
that are known for GHS-R1a expression beyond the field of oncology.

3.3 Experimental
3.3.1

Materials and Methods

All common solvents were purchased from Fisher Scientific. All protected amino acids,
coupling reagents and resins were purchased from Novabiochem, Peptides International
and Chem-Impex and were used without further purification unless otherwise stated. All
reagents were obtained from Sigma-Aldrich. RP-tC18 Sep-Pak SPE and QMA carbonate
SPE cartridges were purchased from Waters. [125I]-Ghrelin was purchased from Perkin
Elmer. Cyclotron produced [18F]H218O was obtained from Dr. Mike Kovacs at the
Cyclotron & PET Radiochemistry Facility at St. Josephs Hospital in London, Ontario,
Canada. For analytical HPLC-MS, a Agilent RP-C18 4.6 x 250 mm, 5 µm column was
used. For semi-preparative HPLC-MS work, an Agilent RP-C18 19 x 150 mm, 5 µm
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column was used. A gradient solvent system was used containing 0.1% TFA in
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). For analytical UHPLC-MS,
studies were performed on a Waters, Inc. Acquity UHPLC H-Class system, combined
with a Xevo QTof mass spectrometer (ES+, cone voltage = 30 V). For analytical
UHPLC-MS studies, a Waters Acquity UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column
was used with a gradient solvent system consisting of 0.1% formic acid in acetonitrile
(solvent C) and 0.1% formic acid in water (solvent D). Analytical radio-RP-HPLC
(AgilentTM RP-C18 column 4.6 x 150 mm, 5 µm) was performed on a Waters 1525
Binary HPLC pump containing a Waters 2487 dual λ absorbance detector, Waters InLine degasser, a gamma detector and Breeze software (version 3.30).

3.3.2

General FMOC Synthesis of Ghrelin(1-8) Peptides

Peptide synthesis was carried out manually using FMOC-based solid-phase peptide
chemistry. Peptides were synthesized at a 0.1 mmol scale on Rink Amide MBHA resin
(0.52 mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF),
followed by Fmoc deprotection using 2 mL of 20% piperidine in N,N-dimethylformamide
(DMF) for two cycles (10 minutes, 5 minutes). Amino acids were preactivated by
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of O-(6-chlorobenzotriazol-1-yl)N,N,N’,N’-tetramethyluronium hexafluorophosphate (HCTU) and 6 eq. of N,Ndiisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin
and vortexed for 60 minutes. These cycles were repeated until all 8 N-terminal amino
acids were coupled to the resin.
Allyloxycarbonyl deprotection of diaminopropionic acid was performed under inert
atmospheric N2 conditions. DCM was dried over sieves for 24 hours before adding 1 mL
to the resin. 2 eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin
followed by 0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM.
The peptide vessel was removed from inert conditions and allowed to react for 30
minutes. The resulting free amine was acylated using 2 eq. of the corresponding acid
(octanoic acid, 4-fluorobenzoic acid, 6-fluoronaphthoic acid or 4’-fluoro-[1,1’-biphenyl]4-carboxylic acid), 2 eq. of HCTU and 6 eq. of DIPEA in DMF. The reaction mixture
was left to couple overnight.
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Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS) and 2.5% water to the resin
and allowed it to mix for 5 hours. The cleaved peptide was precipitated from solution
using ice-cold tert-butyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes)
resulting in a crude peptide pellet. The supernatant was decanted and the resulting peptide
pellet was dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a
white crude powder. Purification was performed using preparative HPLC-MS and purity
of the resulting peptides were analyzed using analytical UHPLC, these results are
summarized in table 3.4.
Table 3.4 Analytical data of ghrelin analogues 3.3-3.3j, 3.4a-3.4b, 3.5a-3.5c, 3.6a-3.6b and 3.7

3.3.3

Competitive Binding Assay (IC50)

The affinity for GHS-R1a was determined using a radioligand competitive binding assay.
Assays were performed using GHS-R1a transfected HEK293 cells as receptor source and
human [125I]-ghrelin(1-28) (PerkinElmer Inc.) as the radioligand. Human ghrelin(1-28)
was used as reference to ensure the validity of the results. A suspension of membrane
from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated with
ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9
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M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25
mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and
0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of
[125I]-ghrelin bound to the membranes was measured by gamma counter. IC50 values
were determined by nonlinear regression analysis to fit a 4 parameter dose response curve
using Prism 6 (Version 6.0c). All binding assays were performed in triplicate.

3.3.4

Synthesis of 6-amino-2-ethylnaphthoate (3.9)

6-Amino-2-naphthoic acid (300 mg, 1.60 mmol) was dissolved in 50 mL of ethanol and
heated to 80 °C while stirring in a 100 mL round bottom. Sulfuric acid was added
dropwise until pH 6 was reached. The reaction was left to reflux overnight. Ethanol was
removed by rotary evaporation and the crude oil was redissolved in dichloromethane and
transferred to a separatory funnel. Compound 3.9 was extracted with 0.1 M sodium
bicarbonate (50 mL) and dichloromethane (3 x 50 mL). The organic fractions were
combined and dried with MgSO4. MgSO4 was removed by gravity filtration and the
resulting solution was removed by rotary evaporation. The crude solid was dissolved in 1
mL of dichloromethane with 0.1 % triethylamine. The crude solution was purified by
flash column chromatography (dichloromethane, 0.1% triethylamine) and tracked by
TLC. The spot at Rf = 0.4 was collected into a 100 mL round bottom and rotary
evaporated to dryness. Pure 3.9 was isolated as a brown solid in 86% yield (295 mg, 1.37
mmol). HRMS: m/z calculated for C13H13O2N, 215.0946; observed 215.0942. 1H-NMR
Spectrum (400 MHz, CDCl3, δ): 8.46 (1H, s, Harom), 7.96 (1H, d, Harom, J = 8 Hz), 7.77
(1H, d, Harom, J = 12 Hz), 7.60 (1H, d, Harom, J = 12 Hz), 7.00-6.97 (2H, m, Harom), 4.42
(2H, q, CH2CH3, J = 8 Hz), 1.43 (3H, t, CH2CH3).

3.3.5

Synthesis of 6-dimethylamino-2-ethylnaphthoate (3.10)

Compound 3.9 (295 mg, 1.37 mmol) was dissolved in 60 mL of methanol in a 250 mL
round bottom and stirred at room temperature. While stirring, 37 %wt formaldehyde (2.0
mL, 27.4 mmol) was added dropwise followed by sodium cyanoborohydride (0.86 g,
13.7 mmol) and was left to stir at room temperature for 12 hours. After 12 hours, starting
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material was still present by thin layer chromatography (TLC) (100% dichloromethane),
therefore the reaction was heated to 40 °C for 4 hours. The reaction mixture was diluted
with 50 mL of fresh dichloromethane and transferred to a separatory funnel. The crude
product was extracted with distilled water (50 mL) and dichloromethane (3 x 50 mL).
The organic fractions were combined and dried with MgSO4. MgSO4 was removed by
gravity filtration and the resulting solution was removed by rotary evaporation to a
yellow solid and dried under high vacuum. The crude solid was dissolved in 1 mL of
10% hexanes in dichloromethane and purified by flash column chromatography (10%
hexanes in dichloromethane) and tracked by TLC. Fractions containing the spot at Rf =
0.55 were combined into a 100 mL round bottom and rotary evaporated. Pure 3.10 was
obtained in 64% yield (213 mg, 0.87 mmol). HRMS: m/z calculated for C15H17O2N,
243.1259; observed 243.1255. 1H-NMR Spectrum (400 MHz, CDCl3, δ): 8.40 (1H, s,
Carom), 7.92 (1H, d, J= 8 Hz, Carom), 7.81 (1H, d, J= 8 Hz, Carom), 7.70 (1H, d, J= 8 Hz,
Carom), 7.28 (1H, d, J= 8 Hz, Carom) 6.96 (1H, s, Carom), 4.33 (2H, q, J = 8 Hz, CH2CH3).
3.06 (6H, s, (CH3)2), 1.35 (3H, t, J = 8 Hz, CH2CH3).

3.3.6

Synthesis of 6-trimethylamino-2-ethylnaphthoate triflate
(3.11)

Compound 3.10 (200 mg, 0.82 mmol) was dissolved in 30 mL of anhydrous
dichloromethane dried over sieves. The round bottom was evacuated and charged with
N2. The reaction mixture was then cooled to 0 °C in an ice bath and methyl
trifluoromethansulfonate (370 µL, 3.28 mmol) was added dropwise using an oven dried
needle and syringe. The reaction was left to stir. Pure 3.11 precipitated out of solution
after 1 hour. The precipitate was collected with a Hirsch funnel and rinsed thoroughly
with cold anhydrous dicholoromethane. The resulting white solid was dried under high
vacuum, with 3.11 being isolated in a 78% yield (260 mg, 0.64 mmol). 1H-NMR
Spectrum (400 MHz, DMSO, δ): 8.77 (1H, s, Carom), 8.62 (1H, s, Carom), 8.47 (1H, d, J= 8
Hz, Carom), 8.17-8.26 (3H, m, Carom), 4.40 (2H, q, J= 8 Hz, CH2CH3) 3.72 (9H, s, (CH3)3),
1.38 (3H, t, J = 8 Hz, CH2CH3). 13C-NMR Spectrum (100 MHz, DMSO, δ): 223.0 (CaromN(CH3)3), 165.9 (C=O), 134.7 (Carom), 132.3 (Carom), 132.1 (Carom), 130.0 (Carom), 130.0
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(Carom), 127.0 (Carom), 120.0 (Carom), 120.0 (Carom), 110.0 (Carom), 62.9 (N-(CH3)3), 61.6
(CH2CH3), 21.4 (CH2CH3).

3.3.7

Synthesis of [19F]-PFPN

6-Fluoronaphthoic acid (200 mg, 1.05 mmol) and pentafluorophenol (211 mg, 1.15
mmol) were dissolved in 100 mL of dichloromethane and cooled to 0 °C in an ice bath.
EDC (30.2 mg, 1.58 mmol) and DMAP (25 mg, 0.21 mmol) were added to the reaction
and stirred. The reaction was tracked by thin-layer chromatography (5% ethyl acetate in
hexanes, Rf = 0.69). After 1 hour, no starting material was visible by TLC. The reaction
was quenched with 30 mL of saturated ammonium chloride (NH4Cl) and transferred to a
250 mL separatory funnel. [19F]-PFPN was extracted with 50 mL of ethyl acetate and
repeated 3 times. The organic layers were combined and dried with magnesium sulphate
(MgSO4). MgSO4 was removed by gravity filtration and the solution was dried using
rotary evaporation. The crude solid was dissolved in 1 mL of 5% ethyl acetate in
hexanes and loaded onto a silica plug and eluted with 5% ethyl acetate in hexanes. [19F]PFPN was isolated as a white solid in 86% yield (322 mg, 0.90 mmol). HRMS: m/z
calculated for C17H6O2F6, 356.0272; observed 356.0279. 1H-NMR Spectrum (400 MHz,
CDCl3, δ): 8.81 (1H, s, Harom), 8.19 (1H, d, Harom, J = 8 Hz), 8.04 (1H, dd, Harom, J = 8 Hz,
2 Hz), 7.93 (1H, d, Harom, J = 8 Hz), 7.57 (1H, d, Harom, J = 8 Hz), 7.41 (1H, dd, Harom, J =
8 Hz, 2 Hz)
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C-NMR Spectrum (100 MHz, CDCl3, δ): 163.9 (C=O), 162.7 (F-Cnaphthyl),

161.4 ((C=O)O-C6F5), 137.5 (C6F5), 137.4 (C6F5), 132.9 (C6F5), 132.4 (C6F5), 132.3
(C6F5), 129.4 (Cnaphthyl), 128.2 (Cnaphthyl), 128.1 (Cnaphthyl), 126.4 (Cnaphthyl), 123.5 (Cnaphthyl),
118.0 (Cnaphthyl), 117.7 (Cnaphthyl), 111.5 (Cnaphthyl), 111.2 (Cnaphthyl).

3.3.8

Radiolabelling Procedure of [18F]-PFPN

To prepare 3.11, Tracerlab FXFN (GE Healthcare) was configured as shown in figure 4.
Vials were loaded as follows: Vial 1: potassium carbonate (2.0 mg), krytofix 2.2.2 (7.0
mg) in 200 µL H2O and 800 µL ACN; Vial 2: 1000 µL anhydrous ACN; Vial 3: 1000 µL
anhydrous ACN; Vial 4: 2 mg of 3.11 in 750 µL DMSO; Vial 5: 20 µL TMAH (1M) in
1000 µL ACN.
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Fluorine-18 was produced on a GE Healthcare PETtrace 880 cyclotron (16.5 MeV) via a
18

O(p,n) nuclear reaction on a high yield Nb25 fluorine-18 target. Fluoride-18 was

delivered in a 2 mL aliquot to a QMA carbonate Sep-Pak to isolate the [18O]H2O from
fluoride-18. The fluoride was then eluted into the reaction vial using the potassium
carbonate/kryptofix solution in Vial 1. The fluoride-18 was azeotropically dried by
heating the reaction vial to 75 °C under full vacuum for 5 minutes. This repeated 2 more
times using the anhydrous ACN in Vials 2 and 3. Once dried, the radiolabelling precursor
3.11 was added to the reaction vial from Vial 4, heated to 120 °C and allowed to react for
10 minutes. Following this reaction, Vial 5 was added to the reaction vial to hydrolyze
the ester, heated to 90 °C for 5 minutes before being cooled to 40 °C and completing the
automated portion of the synthesis. The reactor needle was injected down into the
reaction mixture and helium was pumped into the reaction vial for 3 minutes to transfer
the crude mixture from the reaction vial to a product vial via V14.The crude mixture was
collected into 20 mL scintillation vial containing 7 mL of 0.1% TFA in MilliQ water in
the side chamber and removed for manual synthesis.
The diluted mixture was loaded onto a conditioned tC18 Sep Pak to remove unreacted
fluoride-18. Radiolabelled 3.16 was eluted from the Sep-Pak with 1000 µL of ACN into a
new reaction vial containing 20 mg pentafluorophenol, 10 mg EDC and 1 mg of DMAP.
The mixture was allowed to react at room temperature for 5 minutes before being diluted
with 500 µL of 0.1% TFA in H2O and injected onto the HPLC for semi-preparative
purification (55% to 95% acetonitrile in water with 0.1% TFA). Purified 3.16 was
collected at 9 minutes into a scintillation vial and subsequently evaporated to dryness
using a Biotage Speed Rotary Evaporator for 5 minutes. After evaporation, 3.17 in 750
µL of ACN was added to the scintillation vial followed by 30 µL of DIPEA. The reaction
mixture was left at 40 °C for 20 minutes, diluted to 1500 µL with 0.1% TFA in H2O and
injected on to the HPLC for semi-preparative purification (20% to 80% acetonitrile in
water with 0.1% TFA). Purified 3.18 was collected at 5 minutes for 1.5 minutes into a 10
mL sterile vial resulting in approximately 8 mL of solvent.
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3.3.9

Quality Control of [19F]-PFPN

Using an analytical radio-RP-HPLC equipped with a gamma detector, the radiochemical
purity and identity of 3.18 was confirmed by co-injection with a non-radioactive standard
3.7. Retention times were consistent at 5.0 minutes. 3.18 was obtained in 3.1% decay
correct radiochemical yield and 95% radiochemical purity with a complete synthesis time
of 1.5 hours.
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Chapter 4

4

Synthesis of Monomeric and Dimeric Dye Labelled
Ghrelin(1-8) Analogues for Evaluation in GHS-R1a
Expressing Cells by Fluorescence Microscopy
4.1 Introduction
The growth hormone secretagogue receptor-1a (GHS-R1a) is a G-protein coupled
receptor (GPCR) that is activated by peptidic growth hormone secretagogues to release
growth hormone from the pituitary. This receptor is not solely expressed in the pituitary
and can be found in various other tissues such as the hypothalamus, heart, lung, pancreas,
intestine and adipose.1, 2 When activated by its endogenous ligand, ghrelin, this receptor
performs important roles such as energy homeostasis, body weight control, aging and
cardiac contractility. The endogenous ligand for GHS-R1a was isolated from the rat
stomach in 1990 by Kojima et. al.2 Ghrelin is a 28 amino acid peptide containing a
unique octanoylated serine at residue 3 of the amino acid sequence.
Several peptides, such as neuropeptide Y, cholestokinin and ghrelin, are capable of
stimulating feeding and maintaining a positive energy balance through central or
peripheral administered doses.3-5 What is most intriguing about ghrelin, is its ability to
have a longer acting regulation of body weight rather than a short-term, meal related
regulation found with other peptides, such as cholestokinin. The ghrelin-GHSR-1a axis
has also been implicated in aging. Studies have shown the GHS-R1a regulates the timing
and amplitude of growth hormone release in human subjects and as subjects age, the
amplitude of growth hormone release begins to regress. Administration of ghrelin agonist
analogues to elderly human subjects was shown to increase amplitude of GH release,
increase lean mass in shoulder and knee strength, accelerate the healing process
following a hip fracture as well as increase bone mineral density in postmenopausal
women.6-10 From a therapeutic standpoint, targeting GHS-R1a receptors using ghrelinbased analogues can hold promise for treatment of anorexia, cachexia or other diseases
that cause involuntary weight loss as well as age-dependent functions caused by
suppression of growth hormone.11 Targeting of GHS-R1a is also advantageous for
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diagnosis of cardiomyopathy and cancer. Studies have shown that GHS-R1a is
upregulated in the left ventricular tissue of patients that previously suffered congestive
heart failure. These areas of higher GHS-R1a concentration were visualized using dyelabelled ghrelin analogues and fluorescence microscopy.12-14 GHSR-1a and ghrelin have
also been implicated in many cancer progression processes such as cell proliferation,
migration and apoptosis. GHSR-1a has been identified in a wide range of human cancers
such as pituitary, prostate, breast, and ovarian tumours as well as astrocytoma.15 The
GHS-R1a/ghrelin axis plays an important role in various biological issues that require
therapeutic and diagnostic pharmceuticals. Development of ghrelin-based ligands with
affinity and specificity to GHS-R1a would have a wide range of applications in both
therapeutic and diagnostic fields.
There are several approaches to increasing the affinity and specificity of a targeting
ligand, one method that has proven to be successful is multimerization. Several examples
of multimerization have been demonstrated with RGD to target the integrin receptor αvβ3.
When compared to monomeric RGD, dimeric and tetrameric analogues have shown to
possess improved in vivo kinetics and target affinity.16, 17 The increase in affinity has been
attributed to a higher local concentration of the targeting peptide in the immediate
surroundings of the receptor. Once one unit of the multimer ligand has been bound, the
other units are more likely to have a higher rate of binding and lower rate of dissociation.
This phenomenon leads to higher uptake and longer retention of targeting ligands at the
receptor.18 These aspects of multimerization are valuable when visualizing receptors of
interest and therefore have been applied to various peptides used in optical imaging and
scintillation imaging.16-22
Optical imaging (OI) is a useful tool to visualize molecular targets in living systems
without using radioactive materials required for other imaging modalities, such as
positron emission tomography (PET) and single-photon emission computed tomography
(SPECT). This method of imaging is known to be a cost-effective and robust but
difficulties arise when photons are absorbed or scattered by surrounding tissues. These
difficulties can be addressed by using near-infrared (NIR) light (700-1000 nm) that has
better photon penetration in and out of tissues and therefore more less absorption and
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scattering is caused by tissues. OI can be used to better understand the biology of various
disease states as well as monitor therapy and other biological process.
There are two examples in which fluorescently labelled ghrelin analogues have been used
to detect the GHS-R1a receptor as a biomarker of prostate cancer and cardiomyopathy.13,
23

In the first example, a fluorescein-ghrelin(1-19) analogue was incubated with prostate

core biopsy samples of 13 patients with ranging conditions from normal, benign
hyperplasia (BPH), prostatic interneoplasia (PIN) and prostate cancer. Using OI, the
fluorescent signal of fluorescein-ghrelin(1-19) was 4.7-fold higher in prostate cancer than
BPH and normal prostate tissue. The signal was also 1.9-fold higher in prostate cancer
than PIN. This not only demonstrates the value OI agents have for biomarker screening
of ex vivo biopsy samples using a facile and low cost method of detection, but also
demonstrates the usefulness of ghrelin for accurate detection of prostate cancer from
other states of prostate tissue health. The second example uses a Cyanine5-ghrelin(1-19)
analogue to detect the presence of GHS-R1a during the differentiation of P19-derived
cardiomyocytes through using OI in in vitro and ex vivo assays.
In this study, we propose to synthesize high affinity monomeric and dimeric ghrelin(110) analogues bearing a NIR Cyanine5 dye. These NIR-analogues can be used to
visualize GHS-R1a using flourescence microscopy and holds promise for monitoring
therapies and diagnosis of the various biological processes effected by the GHS-R1a
receptor.

4.2 Results and Discussion
4.2.1

Synthesis and Characterization of a NIR Ghrelin(1-10)
Monomer and Dimer

As discussed in Chapter 3, ghrelin can be truncated to the first 8 N-terminal amino acids
and maintain affinity to GHS-R1a. Through modification of various positions in the 8
amino acid sequence, several analogues were able to selectively target GHS-R1a with
remarkable affinity. Replacing phenylalanine-4 with 1-naphthylalanine (Nal-1) lead to a
48-fold increase in affinity to GHS-R1a while replacing glutamic acid-8 with threonine
lead to a 61-fold increase in affinity than the natural ghrelin(1-8) sequence. These two
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modifications were incorporated into a ghrelin(1-10) monomer and a ghrelin (1-10) dimer
to target GHS-R1a. All the other amino acids were left unchanged except for residue 3,
which was substituted for diaminopropionic acid (Dpr) acylated with octanoic acid. This
substitution replaces the labile ester moeity with an amide for better stability and facile
chemical synthesis. Therefore, the ghrelin(1-8) peptide chosen to be further developed
into a fluorescent ghrelin(1-10) monomer and dimer was; H-GS-Dpr(octanoyl)-(Nal-1)LSPT-NH2.
In order to maintain affinity to GHS-R1a, ghrelin analogues can only be modified
at the C-terminus due to the importance of the N-terminal amine for receptor binding.24
The Cy5-Ghrelin (1-10) monomer (Scheme 4.1) and dimer (Scheme 4.2) were
synthesized using standard Fmoc peptide chemistry on a solid supprt. They were
synthesized with amino acids bearing standard protecting groups, with the exception of
Dpr and Lys, that contained the orthogonal protecting groups methytrityl (Mtt) and
allyloxycarbonyl (Alloc). After automated peptide synthesis of the core amino acid
sequence, the orthogonal protecting groups were selectively removed to acetylate Dpr
with octanoic acid and to incorporate the cyanine-5 (Cy5) on the lysine side chain,
resulting in the 4.4. To synthesize the ghrelin dimer, the first ghrelin unit was synthesized
on solid support using automated peptide synthesis followed by selective deprotection of
the lysine alloc protecting group to couple another Fmoc-lysine(alloc)-OH using standard
coupling conditions. The second lysine introduces another Fmoc-protected N-terminal
amine for the second targeting ghrelin unit to be synthesized using automated peptide
synthesis. Once both ghrelin units were added to the solid support, the Mtt protecting
group is selectively deprotected from both Dpr side chains and the resulting free amines
are acylated with octanoic acid. The final deprotection of alloc on the second lysine side
chain leaves a free amine to couple Cy5 resulting in 4.10. To reduce the negative steric
effects the Cy5 may cause on receptor affinity, the ghrelin(1-8) targeting peptides were
separated from the lysine by a [2-(2-(Fmoc-amino)ethoxy)ethoxy]acetic acid (AEEA)
spacer and are therefore ghrelin(1-10) analogues. Both peptides were cleaved from the
resin and all standard protecting groups removed using strong acid before being purified
by reverse-phase preparative HPLC. The yeilds and purities are summarized in Table 1.
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Table 4.1 Analytical data for 4.4 and 4.10
Ghrelin
Analogue

[M+2H]2+
Expected

[M+2H]2+
Observed
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Purity

4.4
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98%

4.10

1547.3027

1547.9197
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Scheme 4.1 Synthesis of monomer (4.4). a. 2% TFA, 5% TIS in DCM, b. octanoic acid (3 eq.),
HCTU (3eq.), DIPEA (6 eq.) c. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, d. sulfo-Cy5 NHS
ester (1 eq.), DIPEA (2 eq.) in DMF, e. 95% TFA, 2.5% H2O, 2.5% TIS

(2 eq.) in DMF, n. 95% TFA, 2.5% H2O, 2.5% TIS
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Scheme 4.2 Synthesis of dimer (4.10). f. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, g. Fmoc-

Lys(alloc)-OH (3 eq.), HCTU (3 eq.), DIPEA (6 eq.) in DMF, h. 20% piperidine in DMF (3 mL), i.

Automated peptide synthesis, j. 2% TFA, 2% TIS in DCM, k. octanoic acid (6 eq.), HCTU (6 eq.),

DIPEA (12 eq.) l. Pd(PPH3)4 (0.035 eq.), PhSiH3 (2 eq.), DCM, m. sulfo-Cy5 NHS ester (1 eq.), DIPEA
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4.2.2

Binding Affinity of 4.4 and 4.10 to GHS-R1a

The binding affinity of each peptide was measured using a competitive binding assay
against

125

I-Ghrelin(1-28). Varying concentrations of the monomer and dimer were

incubated with HEK293 cells transfected with GHS-R1a in the presence of 125I-ghrelin(128). As the concentration of the monomer and dimer was increased,

125

I-ghrelin(1-28)

was competitively displaced and quantified into sigmoidal curve (Figure 4.2). The halfmaximal concentration (IC50) can be extracted from these curves and used to quantify the
binding affinity to GHS-R1a.
From the IC50 curves, the monomer (4.4) had 26.3 nM affinity while the dimer (4.10) had
50.0 nM affinity. As reported in Chapter 2, the IC50 of the unmodified ghrelin(1-8)
sequence is 200 nM. The monomer and dimer were able to achieve 7.6 and 4.0-fold
increase in affinity, respectively. This is the opposite trend than expected. Dijkgraff et al.
studied the multimerization of [68Ga]-RDG peptides by synthesizing a homomonomer,
dimer and tetramer. The binding affinity to integrin αvβ3 became stronger as more RGD
units were added. The monomer, dimer and tetramer had IC50 values of 23.9 nM, 8.99 nM
and 1.74 nM respectively. Multimerization of ghrelin did not produce the same trend
although tetrameric analogues were not studied.21

Figure 4.1 Competitive binding curves in HEK293/GHS-R1a cells and IC50 (nM) values for 4.4 (A) and
4.10 (B)
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4.2.3

In Vitro Fluorescence Imaging in HT1080 and HT1080/GHSR1a

The subcellular localization of 4.4 and 4.10 were evaluated in the HT1080 (GHS-R1a
negative) cell line and the HT1080/GHS-R1a (GHS-R1a positive) cell line. Each peptide
was diluted with DMSO into a 0.5 µM solution and incubated with each cell line for 1
hour at 37 °C. The cells were then rinsed with serum-free media and PBS before fixed to
microscope slides with 4% paraformaldehyde. Cyanine5 has an excitation maximum of
646 nm and emission maximum of 662 nm, therefore the slides were irradiated with 636
nm light for excitation and emissions were collected using a 663-738 nm filter to
visualize the dye-labelled fluorescence. DAPI stained nuclei were irradiated with 402 nm
light and emissions were collected using a 425 – 475 nm filter. The images were then
overlaid into the merge images.

Figure 4.2 Confocal microscopy results of 4.4 and 4.10 with HT1080 (GHS-R1a negative) and
HT1080/GHS-R1a (GHS-R1a positive) (magnification x 60).
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The obtained fluorscence images are shown in Figure 4.2. Contrary to the IC50 results, 4.4
had little localization in both cell lines. Within the HT1080/GHS-R1a images, it appears
that there are areas of highly concentrated fluorescence on the cell surface that are not
present in the HT1080 cell line. This could be due the higher expression of the target
receptor although the difference of fluorescence in each cell line was hypothesized to be
much greater. 4.10, which possessed the lower affinity to GHS-R1a based off the IC50 had
high fluorescence in both cell lines. The fluorescence in HT1080 cells appears uniform
along the cell surface while the fluorescence appears less uniform and more concentrated
into specific areas on the cell surface of the HT1080/GHS-R1a cells. This is the same
trend seen with 4.4. The high fluorescence of 4.10 in HT1080 cells suggest that creating a
dimer of ghrelin has effect the in vitro properties of peptide and lead the peptide to nonpreferentially binding to the cell surface. This is undesirable as the peptide can no longer
be used to distinguish between GHS-R1a expression. Western blot analysis is underway
with HT1080 and HT1080/GHS-R1a cells to confirm the expression of GHS-R1a in each
cell line. These results will provide an explanation regarding the low uptake of the
monomer 4.4 that is unexpected with an IC50 of 25.3 nM.

4.3 Conclusions
The many biological roles effected by GHS-R1a make this a beneficial pharmacological
target for various therapeutic and diagnostic applications that require specific and
prolonged interaction of a targeting entity with the receptor. As mentioned in Chapter 2,
ghrelin(1-8) analogues are capable of targeting GHS-R1a with high affinity and using the
emerging field of multimerization, held promise to become higher affinity and longer
acting ghrelin targeting entities. Unfortunately, dimerizing a high affinity ghrelin(1-8)
analogue and introducing a NIR dye caused detrimental effects on binding affinity. The
dimerized peptide also developed non-preferential cell surface binding when dimerized
and therefore were not ideal OI agents for GHS-R1a. Liu et al. compared the
pharmacokinetic properties of two RGD dimers with differing chain lengths between the
homodimeric units. One RGD dimer contained 15 atom linker while the other RGD
dimer contained a 47 atom linker. The extra chain length increased the in vitro binding
affinity, but more importantly, resulted in better tumour to background ratios.19
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Therefore, it is advantageous to further investigate the optimal chain length between
ghrelin units in order to obtain better binding affinity and in vitro kinetics of these
dimers. Other structural changes such as using a different ghrelin(1-8) sequence, or
another NIR dye may also have a positive effect on these dimer properties.

4.4 Experimental
4.4.1

Materials and Methods

All common solvents were purchased from Fisher Scientific. All protected amino acids,
coupling reagents and resins were purchased from Novabiochem, Peptides International
and Chem-Impex and were used without further purification unless otherwise stated. All
reagents were obtained from Sigma-Aldrich. [125I]-Ghrelin(1-28) was purchased from
Perkin Elmer. For analytical HPLC-MS, an Agilent RP-C18 4.6 x 250 mm, 5 µm column
was used. For semi-preparative HPLC-MS work, an Agilent RP-C18 19 x 150 mm, 5 µm
column was used. A gradient solvent system was used containing 0.1% TFA in
acetonitrile (solvent A) and 0.1% TFA in water (solvent B). For analytical UHPLC-MS,
studies were performed on a Waters, Inc. Acquity UHPLC H-Class system, combined
with a Xevo QTof mass spectrometer (ES+, cone voltage = 30 V). For analytical
UHPLC-MS studies, a Waters Acquity UHPLC BEH C18 2.1 x 50 mm, 1.7 µm column
was used with a gradient solvent system consisting of 0.1% formic acid in acetonitrile
(solvent C) and 0.1% formic acid in water (solvent D).

4.4.2

Automated Peptide Synthesis of 4.4

Automated peptide synthesis was carried out using a Biotage Syrowave synthesizer and
all amino acids contained standard protecting groups with the exception of Dpr and Lys
that contained methyltrityl (Mtt) and allyloxycarbonyl (Alloc) orthogonal protecting
groups, respectively. The N-terminal glycine contained a BOC protecting group rather
than Fmoc. 4.4 was synthesized at a 0.1 mmol scale on Rink Amide MBHA resin (0.52
mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF) followed
by two cycles (10 minutes, 5 minutes) of Fmoc deprotection using 2 mL of 20%
piperidine in N,N-dimethylformamide (DMF). Amino acids were preactivated by
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq. of N,N-
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diisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin
and coupled for 60 minutes. These cycles were repeated until all 10 N-terminal amino
acids were coupled to the resin in the following sequence; H-GS-Dpr(mtt)-Nal-1-LSPTAEEA-Lys(Alloc)-Rink Amide MBHA Resin.
Mtt deprotection of diaminopropionic acid was performed using vortexing the resin with
2 mL of 2% TFA and %5 TIS in dichloromethane for 2 minutes. The resin was then
rinsed well with dichloromethane. This method was repeated 8 times, or until the solution
no longer appeared yellow. Following the deprotection, the resin was vortexed with 200
µL of DIPEA in DMF to neutralize any residual TFA. Octanoic acid (3 eq.) was coupled
to the Dpr free amine using HCTU (3 eq.) and DIPEA (6 eq.) in DMF. The resin was
vortexed for 1 hour.
Allyloxycarbonyl deprotection of lysine was performed under inert atmospheric N2
conditions. DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2
eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by
0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide
vessel was removed from inert conditions and allowed to react for 30 minutes. The resin
was thoroughly rinsed with dichloromethane and subsequently dried by passing air over
the resin. The dried resin was weighed and 10% of the total resin was transferred to a new
peptide vessel to couple to the NIR dye. The lysine free amine was coupled to sulfocyanine5 NHS ester (1 eq.) using 50 µL of DIPEA in 0.5 mL of DMF. The peptide vessel
was covered in foil and allowed to vortex overnight. The resin was thoroughly washed
with DMF and dichloromethane.
Full deprotection and cleavage from solid support was performed by adding a 1 mL
mixture of 95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5
hours in the dark. The cleaved peptide was precipitated from solution using ice-cold tertbutyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude
peptide pellet. The supernatant was decanted and the resulting peptide pellet was
dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a blue crude
powder. Purification was performed using preparative HPLC-MS and purity of the
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resulting peptides were analyzed using analytical UHPLC. HRMS (ESI+): m/z calculated
for C91H131N15O23S2, [M+2H]2+ = 934.4612, observed [M+2H]2+ = 934.1838.

4.4.3

Automated Peptide Synthesis of 4.10

Automated peptide synthesis was carried out using Biotage Syrowave and all amino acids
contained standard protecting groups with the exception of Dpr and Lys that contained
methyltrityl (Mtt) and allyloxycarbonyl (Alloc) orthogonal protecting groups,
respectively. The N-terminal glycine contained a BOC protecting group rather than
Fmoc. 4.10 was synthesized at a 0.1 mmol scale on Rink Amide MBHA resin (0.52
mmol/g). The resin was initially swelled with N,N-dimethylformamide (DMF) followed
by two cycles (10 minutes, 5 minutes) of Fmoc deprotection using 2 mL of 20%
piperidine in N,N-dimethylformamide (DMF). Amino acids were preactivated by
combining 3 eq. of Fmoc-protected amino acid, 3 eq. of HCTU and 6 eq. of N,Ndiisopropylethylamine (DIPEA) in 2 mL of DMF. The mixture was added to the resin
and coupled for 60 minutes. These cycles were repeated until all 10 N-terminal amino
acids were coupled to the resin in the following sequence; H-GS-Dpr(mtt)-Nal-1-LSPTAEEA-Lys(Alloc)-Rink Amide MBHA Resin.
Allyloxycarbonyl deprotection of lysine was performed under inert atmospheric N2
conditions. DCM was dried over sieves for 24 hours before adding 1 mL to the resin. 2
eq. of phenylsilane in 1 mL dry DCM was then added to the peptide resin followed by
0.045 eq. of tetrakis(triphenylphosphine) palladium (0) in 1 mL dry DCM. The peptide
vessel was removed from inert conditions and allowed to react for 30 minutes. The resin
was thoroughly washed with dichloromethane and DMF before being manually coupled
to Fmoc-Lys(alloc)-OH (3 eq.) using HCTU (3 eq.) and DIPEA (6 eq.) in 2 mL of DMF.
The resin was vortexed for 1 hour and thoroughly rinsed with DMF before being placed
on the Biotage Syrowave to continue the automated synthesis of the second ghrelin unit
of the dimer. Upon completion of automated synthesis, the second Dpr(Mtt) was
deprotected using the same Mtt deprotection protocol explained above and couple to
octanoic acid using the same coupling conditions. The second Lys(alloc) was deprotected
using the same method listed above and thoroughly rinsed with dichloromethane before
drying the resin by passing air over it. The resin was also weighed and 10% of the resin
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was transferred to a new peptide vessel. The free amine was coupled to sulfo-cyanine5
NHS ester (Lumiprobe, 1 eq.) with 200 µL of DIPEA in 1 mL of DMF. The resin was
vortexed in the dark overnight before being thoroughly rinsed with DMF and
dichloromethane.
Full deprotection and cleavage from solid support was performed by adding a 1 mL
mixture of 95% TFA, 2.5% TIS and 2.5% water to the resin and allowed it to mix for 5
hours in the dark. The cleaved peptide was precipitated from solution using ice-cold tertbutyl methyl ether (TBME) and centrifuged (3000 rpm, 10 minutes) resulting in a crude
peptide pellet. The supernatant was decanted and the resulting peptide pellet was
dissolved in 20% acetonitrile in water, frozen at -78 °C and lyophilized to a blue crude
powder. Purification was performed using preparative HPLC-MS and purity of the
resulting peptides were analyzed using analytical UHPLC. HRMS (ESI+): m/z calculated
for C150H233N27O39S2, [M+2H]2+ = 1547.3027, observed [M+2H]2+ = 1547.9197.

4.4.4

Competitive Binding Assay (IC50)

The affinity for GHS-R1a was determined using a radioligand competitive binding assay.
Assays were performed using GHS-R1a transfected HEK293 cells as receptor source and
human [125I]-ghrelin(1-28) (PerkinElmer Inc.) as the radioligand. Human ghrelin(1-28)
was used as reference to ensure the validity of the results. A suspension of membrane
from HEK293/GHS-R1a cells (50,000 cells per assay tube) were incubated with
ghrelin(1-8) peptide analogues (at concentrations of 10-5 M, 10-6 M, 10-7 M, 10-8 M, 10-9
M, 10-10 M and 10-11 M) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25
mM HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and
0.4% BSA, pH 7.4). The resulting suspension was incubated for 20 minutes under
shaking (550 rpm) at 37 °C. Unbound [125I]-ghrelin was removed and the amount of
[125I]-ghrelin bound to the membranes was measured by Gamma counter. IC50 values
were determined by nonlinear regression analysis to fit a 4 parameter dose response curve
using GraphPad Prism 6 (Version 6.0c). All binding assays were performed in triplicate.
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4.4.5

Fluorescence Microscopy of 4.4 and 4.10 with GHS-R1a

Monomer 4.4 and dimer 4.10 were dissolved in DMSO for a concentration of 1 mM.
Dye stocks were subsequently diluted in serum-free Dulbecco's modified Eagle's medium
media (DMEM) supplemented with Penicillin-Streptomycin (Pen-Strep) to a final
concentration of 0.5 µM.
Affinity of dye-labelled peptide was tested towards HT1080 fibrosarcoma cells (ATCC)
and HT1080 fibrosarcoma cells stably transfected with GHS-R, transcript variant 1a
(OriGene Technologies Inc.). HT1080 and HT1080/GHSR1a cell lines were seeded onto
coverslips at 50,000 cells per well in a 12-well plate format. Cells were incubated
overnight in DMEM supplemented with 10% fetal bovine serum (FBS) and Pen-Strep at
37 °C in a 5% CO2 atmosphere. Media was removed and cells washed once with serumfree media and twice with phosphate buffer saline (PBS). Cells were then incubated with
1 mL of 0.5 µM 4.4 or 4.10 in serum-free media for 1 hour at 37°C in a 5% CO2
atmosphere. Cells were washed once with serum free media and twice with phosphate
buffer saline (PBS), fixed with 4% paraformaldehyde for 15 minutes and mounted onto
slides containing Pro-Long Antifade® mounting medium with 4',6-diamino-2phenylindole (DAPI). Images were obtained using a Nikon A1R confocal microscope.
4.4 and 4.10 were visualized with excitation at 636 nm and emission collected between
663−738 nm. DAPI was visualized with excitation at 402 nm and emission collected
between 425-475 nm.
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Chapter 5

5

Conclusions

5.1 Outlook and Conclusions
This thesis provides an example of how a natural receptor-ligand complex can be
exploited for diagnostic and therapeutic purposes. Ghrelin, being the endogenous ligand
for GHS-R1a, provided a high affinity template to begin modifying, as well as a “goldstandard” to compare the success of other ghrelin analogues.1 The modifications to
ghrelin were made rationally based off previous ghrelin literature and used classical
approaches to increasing in vivo affinity and stability, as well as standard approaches to
incorporating signaling sources, such as optical dyes and radionuclides. The methods led
to various ghrelin analogues with high affinity to GHS-R1a and only a few were further
evaluated as optical or scintigraphical imaging agents. The lead analogues are
summarized in table 5.1
Table 5.1 Summary of all ghrelin analogues synthesized and the corresponding IC50.
Chapter

Ghrelin Analogue

IC50 (nM)

2

Dpr3(octanoyl), Lys19([69/71Ga]-DOTA)-Ghrelin(1-19)

5.67

3

Inp1,Dpr3(6-fluoro-2-napthyl),Nal-14,Thr8-Ghrelin(1-8)

0.16

4

Dpr3(octanoyl), Nal-14, Thr8, AEEA9,Lys10-Ghrelin(1-10)monomer

25.3

4

Dpr3(octanoyl), Nal-14, Thr8, AEEA9,Lys10-Ghrelin(1-10)dimer

50.0

The first generation ghrelin analogue, [Dpr3(octanoyl), Lys19(68Ga-DOTA)]-ghrelin(1-19)
(2.3d), was capable of targeting GHS-R1a with similar affinity to ghrelin(1-28) when
chelated to gallium-68 and was shown to selectively target GHS-R1a in blocking studies.
While 2.3d was capable imaging GHS-R1a in vivo, preclinical studies in HT1080 and
HT1080/GHS-R1a raised two concerns; relatively low localization to the tumour and
retention of the radioactivity in kidneys. While this analogue supported the capability of
ghrelin to be used as an in vivo PET imaging agent, there were modifications required to
provide sufficient tumour uptake, optimal tumour-to-background ratios and overall
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improved pharmacokinetics. These findings further developed this thesis into the second
generation of ghrelin(1-8) analogues.
In an effort positively affect the pharmacokinetic properties of the next generation of
ghrelin analogues, many of the C-terminal amino acids were removed. This would
hypothetically remove many amino acid side chain charges and decrease retention in the
kidneys. Unfortunately, this would also have a detrimental effect on binding affinity.
Systematic modifications were made to residues 1, 3, 4 and 8 in order to optimize ligandreceptor interactions and increase binding affinity to GHS-R1a. Various substitutions of
natural and unnatural amino acids at these residues successfully resulted in many
ghrelin(1-8) analogues with equal or better binding affinity to GHS-R1a. This also
introduced an unnatural element to ghrelin(1-8) useful for increasing in vivo stability.
This generation of analogues was developed with fluorine-bearing side chain
modification at residue 3 to allow translation to a fluorine-18 imaging agent. New
radiochemical procedures were devised for the prosthetic group [18F]-PFPN and through
synthesis of an active ester, [18F]-PFPN was successfully coupled to the lead ghrelin(1-8)
analogue, H-Inp-S-Dpr-Nal-1-LSPT-NH2, This new ghrelin(1-8) fluorine-18 imaging
agent ([18F]-3.7) was obtained in 3.6% d.c. yield. The high specificity to GHS-R1a is an
exciting discovery and preclinical studies are still required to determine if these
modifications had a positive affect kidney retention, in vivo stability and overall
pharmacokinetics.
The final chapter investigated a new approach to optimizing in vivo pharmacokinetics of
pepetide-based targeting entities by employing multimerization. Other well-studied
targeting peptides, such as RGD and bombesin resulted in better binding affinity and in
vivo biodistribution profiles when dimeric and tetrameric peptides were compared to the
monomeric counterparts.2, 3 Two dye labelled ghrelin analogues, a monomer (4.4) and a
dimer (4.10), were synthesized to determine if the same trend resulted from
multimerization of ghrelin. Adding a second unit resulted in a negative effect on binding
affinity and in vitro properties. Upon dimerization, 4.10 showed non-preferential binding
in both of the studied cell lines and in turn, is not able to differentiate between GHS-R1a
expression levels. These results should not deter those from developing different
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dimerized ghrelin analogues as slight modifications to the structures will affect the
biological properties.4 An extensive look into 10 amino acid sequence and employing the
methods mentioned in Chapter 1.4 could result in a more effective ghrelin dimer. It
would be advantageous to investigate the chain length between ghrelin units by
synthesizing longer linkers, and using variations of hydrophilic and hydrophobic linkers.5
It would also be beneficial to study other multimer types of ghrelin such as trimer and
tetramer analogues as the most successful of the RGD multimers is an octamer.2 The
positioning of the signaling source at the end of the lysine chain makes it easy to
investigate other optical dyes, or to incorporate radiometals via chelators or other
radionuclides using prosthetic group or direct group labeling.
Previous to the research stated in this thesis, little work had been done on the synthesis of
ghrelin analogues as PET or SPECT imaging agents. In 2009, non-radioactive ghrelin (15) and ghrelin(1-14) analogues were synthesized to explore whether or not ghrelin was
capable of tolerating fluorine and rhenium modifications to residue 3. The ghrelin(1-14)
analogues set the stage for PET imaging potential with ghrelin, but were not further
developed.6 In 2014, a ghrelin(1-6) peptide was labelled with monodentate and tridentate
technetium-99m complexes. These peptides had respectable IC50 values of 45 nM and 54
nM for GHS-R1a but biodistribution studies revealed that this analogue mainly localized
to the kidneys.7 The research in this thesis extended the knowledge of long and short
ghrelin analogues as PET imaging agents that was an area previous under studied. It
provides solid ground work for others to continue optimizing ghrelin in order to improve
pharmacokinetic properties and design a strong diagnostic and therapeutic peptide
molecular imaging probe.
When drawing similarities between the works, it must be noted that ghrelin has shown
undesirable biodistribution profiles independent of the ghrelin length. As mentioned in
the introductory material, kidney uptake can be reduced by co-administering megalin or a
cationic amino acid, but these approaches do not address the issue with the peptide
targeting entity directly. There is a particular characteristic about ghrelin analogues that
causes this phenomenon. It would be interesting to use combinatorial methods, such as
one-bead-one-compound, to synthesize a large library of unrelated peptide sequences that
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could retain affinity to GHS-R1a without the attraction to kidney.8 These types of
combinatorial libraries have become more sophisticated and are able to incorporate nonradioactive counterparts to common radionuclides in order to create a targeting entity that
requires the signaling source for affinity to the receptor, much like the analogues
synthesized in Chapter 3.9
There is another family of peptides that are well-known for targeting GHS-R1a that are
structurally different to natural ghrelin. The discovery of these peptides began with
enkephalin (H-TGGFM-OH) in 1977 and through the work of many research groups,
resulted in many more analogues synthesized by 1995.10-14 These small synthetic peptides
were capable of releasing growth hormone in in vivo studies and were grouped into a
family known as growth hormone secretagogues. It was this family of peptides that
helped lead to the discovery of the receptor GHS-R1a in 1996.15 These peptides already
have good affinity for GHS-R1a and would not require optimization by truncation. Using
the classical methods to optimize peptide sequences detailed in Chapter 1, these peptides
could also targeting GHS-R1a with the affinity that the synthesized truncated ghrelin
analogues are capable of. Incorporating a molecular imaging signaling source, such as a
radioisotope or optical dye, could result in larger scope of peptides capable of imaging
GHS-R1a using imaging modalities. There is value in finding other peptide analogues
capable of targeting GHS-R1a to determine what is the most reliable method for
detection.
Overall, this thesis delved into the versatility of ghrelin and its ability to target its
endogenous receptor, GHS-R1a. In vitro and in vivo assays clearly demonstrate that
ghrelin is able to tolerate substantial truncations to the C-terminal region of the natural
amino acid sequence and using well-known approaches to modifying peptides, varying
lengths of ghrelin analogues effectively targeted GHS-R1a. Although more research is
required to validate all these peptides, it is evident they hold potential to be effective
imaging agents for the various conditions and diseases that are regulated by GHS-R1a
expression.
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6
6.1

Appendix

Chapter 2 HPLC Traces

HPLC of 2.3d: Analytical 20 – 60 % acetonitrile in water - 15 minutes
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HPLC of [69/71Ga]-2.3d: Analytical 30 – 80 % acetonitrile in water - 15 minutes
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6.2

Chapter 3 HPLC Traces

HPLC for 3.3: Analytical 30 – 90 % acetonitrile in water – 15 minutes
AH-01-93-1_QC2_30to90_15min_xbridge

2: Diode Array
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HPLC for 3.3b: Analytical 20 – 80 % acetonitrile in water – 15 minutes
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HPLC for 3.3d: Analytical 30 – 90 % acetonitrile in water – 15 minutes
AH-01-93-2_QC1_30to90_15min_xbridge

2: Diode Array
Range: 1.458e+1
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HPLC for 3.3e: Analytical 30 – 90 % acetonitrile in water – 15 minutes
AH-01-93-3_QC1_30to90_15min_Sunfire2

2: Diode Arra
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HPLC for 3.3f: Analytical 30 – 90 % acetonitrile in water – 15 minutes
AH-01-93-4_QC1_30to90_15min_Sunfire2

2: Diode Array
Range: 3.704
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HPLC for 3.3g: Analytical 30 – 90 % acetonitrile in water – 15 minutes
AH-01-93-3_QC1_30to90_15min_Sunfire2

2: Diode Array
Range: 1.64
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UHPLC for 3.3h: Analytical 10 – 60 % acetonitrile in water – 4 minutes
CC-06-099-dThr-F5-10to60

3: Diode Array
Range: 6.111e+1
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HPLC for 3.3i: Analytical 10 – 60 % acetonitrile in water – 4 minutes
CC-06-099-BHT-F5-10to60

3: Diode Array
Range: 5.981e+1
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HPLC for 3.3j: Analytical 20 – 80 % acetonitrile in water – 15 minutes

HPLC for 3.4c: Analytical 10 – 60 % acetonitrile in water – 15 minutes
CC-06-041-QC11_10to60

3: Diode Array
Range: 1.909e+2
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HPLC for 3.5a: Analytical 32 – 70 % acetonitrile in water – 15 minutes

AH-01-51_QC#4_32to70_15min_sunfire_rerun 2: Diode Array
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HPLC for 3.5c: Analytical 32 – 80% acetonitrile in water – 15 minutes
AH-01-079_QC#2_32to80_15min_Atlantis
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UHPLC for 3.6a: Analytical 10 – 60 % - 4 minutes
CC-08-007-1-25

4: Diode Array
Range: 9.235e+1
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UHPLC for 3.6b: Analytical 20 – 70 % - 4 minutes
CC-08-007-2-24

4: Diode Array
Range: 8.095e+1
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UHPLC for 3.7: Analytical 20 – 70 % - 4 minutes
CC-07-137-C4naphthyl_F34

4: Diode Array
Range: 9.717e+1

1.92

8.0e+1
7.5e+1
7.0e+1
6.5e+1
6.0e+1
5.5e+1
5.0e+1
4.5e+1

AU

4.0e+1
3.5e+1
3.0e+1
2.5e+1
3.45

2.0e+1
1.5e+1
1.0e+1
5.0
0.0
-5.0
-1.0e+1
-0.00

0.25

0.50

0.75

1.00

1.25

1.50

1.75

2.00

2.25

2.50

2.75

3.00

3.25

3.50

3.75

Time
4.00

UHPLC for 3.17: Analytical 10 – 60 % - 4 minutes
CC-08-007-7_10to60

4: Diode Array
Range: 6.87e+1
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6.3

Chapter 3 ESI+ Mass Spectrums

ESI+ Mass Spectrum for 3.3

ESI+ Mass Spectrum for 3.3b

98

ESI+ Mass Spectrum for 3.3d
AH-01-93-2_QC1_30to90_15min_xbridge 170 (3.142) Cm (158:182)
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ESI+ Mass Spectrum for 3.3e
AH-01-93-3_QC1_30to90_15min_Sunfire2 428 (7.911) Cm (416:439)

1: Scan ES+
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ESI+ Mass Spectrum for 3.3f
AH-01-93-4_QC1_30to90_15min_Sunfire2 453 (8.373) Cm (445:461)

1: Scan ES+
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ESI+ Mass Spectrum for 3.3g
AH-01-93-3_QC1_30to90_15min_Sunfire2 428 (7.911) Cm (416:439)

1: Scan ES+
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ESI+ Mass Spectrum for 3.3h
CC-06-099-dThr-F5-10to60 1249 (1.804) Cm (1235:1356)

1: TOF MS ES+
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ESI+ Mass Spectrum for 3.3i
CC-06-099-BHT-F5-10to60 1224 (1.761) Cm (1224:1322)

1: TOF MS ES+
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ESI+ Mass Spectrum for 3.3j

ESI+ Mass Spectrum for 3.4c
CC-06-041-QC11_10to60 1310 (1.892) Cm (1301:1440)

1: TOF MS ES+
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ESI+ Mass Spectrum for 3.5a
AH-01-51_QC#4_32to70_15min_sunfire_rerun 329 (6.081) Cm (320:341)
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ESI+ Mass Spectrum for 3.5c
AH-01-79_QC#2_32to80_15min_sunfire 348 (6.432) Cm (333:382)
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ESI+ Mass Spectrum for 3.6a
CC-08-007-1-25 113 (2.106) Cm (112:116)

1: TOF MS ES+
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ESI+ Mass Spectrum for 3.6b
CC-08-007-2-24 117 (2.182) Cm (116:120)
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ESI+ Mass Spectrum for 3.7
CC-07-137-C4naphthyl_F34 105 (1.959)

1: TOF MS ES+
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ESI+ Mass Spectrum for 3.17
CC-08-007-7_10to60 53 (0.990) Cm (51:57)

1: TOF MS ES+
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6.4

Chapter 3 IC50 Curves

IC50 curve for 3.3
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% 125I-Ghrelin of
total bound peptide

IC50 curve for 3.3c
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IC50 curve for 3.3e
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% 125I-Ghrelin of
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IC50 curve for 3.3g
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total bound peptide

IC50 curve for 3.3i
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IC50 curve for 3.4c
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Chapter 3 1H NMR

6.5

7.79

H-NMR of 3.4c (4’-FBC) in DMSO
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1.43

H-NMR of 3.9 in CDCl3
PROTON_CC-07-077-F10-1501
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3.06

H-NMR of 3.10 in DMSO
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3.72

H-NMR of 3.11 in DMSO
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8.81

H-NMR of 3.13 in CDCl3
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6.6

Chapter 4 UHPLC Traces

UHPLC for 4.4: Analytical 10 – 60 % acetonitrile in water – 4 minutes
CC-08-023-Cy5-F14B

4: Diode Array
Range: 3.038e+1

0.26
0.32

1.2e+1
1.0e+1
8.0
6.0
4.0

1.81

2.0

AU

-7.5e-7
-2.0
-4.0
-6.0
-8.0
-1.0e+1
-1.2e+1
-1.4e+1
-1.6e+1
-0.00

0.25

0.50

0.75

1.00

1.25

1.50

1.75

2.00

2.25

2.50

2.75

3.00

3.25

3.50

3.75

Time

UHPLC for 4.10: Analytical 10 – 60 % acetonitrile in water – 4 minutes
CC-08-031-F29

4: Diode Array
Range: 5.33e+1
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Chapter 4 ESI+ Mass Spectrums

6.7

ESI+ Mass Spectrum for 4.4
CC-08-023-Cy5-F14B 99 (1.845)
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ESI+ Mass Spectrum for 4.10
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1032.3191

%

0
700

1: TOF MS ES+
2

1547.8948

100

800

900

1000

1546.8726

1100

1200

1300

1400

1500

1569.8425

1600

1700

1800

1900

m/z

120

Curriculum Vitae
ACADEMIC EXPERIENCE
Sept. 2011 – Feb 2016:

PhD Student at The University of Western Ontario
Supervisor: Dr. Leonard Luyt
Ph.D. Thesis: Design and Synthesis of Ghrelin Analogues
as Non-Invasive GHS-R1a Imaging Probes

Apr. 2010 – Aug. 2010

CaRTT Summer Studentship at The London Regional
Cancer Center
Supervisor: Dr. Leonard Luyt
Project Title: Peptide Mimics of Hyaluronan as Molecular
Imaging Probes for Rhamm-Expressing Carcinomas

Sept. 2010 – Apr. 2011

Fourth year Honours Project at Dalhousie University
Supervisor: Dr. Norman Schepp
Honours Thesis: Effect of Media Polarity on Two-Photon
Photochemistry of BODIPY and Stilbene Derivatives

TEACHING EXPERIENCE
2015

Resource Room Instructor for Organic Chemistry of
Biological Molecules, The University of Western Ontario

2011 – 2014

Teaching Assistant for Organic Chemistry of Life Sciences,
The University of Western Ontario

2011 – 2014

Teaching Assistant for Organic Chemistry of Biological
Molecules, The University of Western Ontario

HONOURS AND AWARDS
2015

Travel Award, Society of Radiopharmaceutical Sciences,
Columbia, MO, USA.

2014

Poster Award, Imaging Applications in Prostate Cancer,
London, ON, CA.

2013

Travel Award, Society of Radiopharmaceutical Sciences,
Jeju, South Korea.

121

2012

Poster Award, CIHR Oncology Research and Education
Dat, London, ON, CA.

2011 – 2014

Western Graduate Research Scholarship

2011

Dean’s List, Dalhousie University

2010

CaRTT Summer Studentship, London Regional Cancer
Centre, London, ON. CA.

2009

In-Course Scholarship, Dalhousie University

2008

Dean’s List, Dalhousie University

2008

Entrance Scholarship, Dalhousie University

PUBLICATIONS
•
•

Charron, C. L.; Hickey, J.; Cruickshank, D. Nsiama, T.; Luyt, L.G., Molecular Imaging Probes
Derived from Natural Peptides, Nat. Prod. Rep., 2016.
Douglas, G. A. F.; McGirr, R.; Charlton, C. L.; Kagan, D. B.; Hoffman, L. M.; Luyt, L. G.;
Dhanvantari, S. Characterization of a far-red analog of ghrelin for imaging GHS-R in P19-derived
cardiomyocytes. Peptides, 2014, 54, 81-88.

PUBLISHED ABSTRACTS
•

•

Charlton, C.L.; McGirr, B; Dhanvantari, S; Kovacs, M; Luyt, L. [68Ga] Labeled Ghrelin (1-19)
Analogue for Targeting Growth Hormone Secretagogue Receptor. 20th International Symposium
for Radiopharmaceutical Sciences, 2013, J. Labelled Cpmds. Radiopharm. 56, S192.
Charlton, C.L.; Hou, J.Q; McGirr, R; Dhanvantari, S; Lee, T-Y; Kovacs, M; Luyt, L.
Development of High Affinity Ghrelin(1-8) Analogues for Imaging GHSR-1a with Fluorine-18,
21st International Symposium for Radiopharmaceutical Sciences, 2015, J. Labelled Cpmds.
Radiopharm. 58, S177

CONFERENCE ABSTRACTS
•

•

•

•

•

Charlton, C.L.; Hou, J.Q; McGirr, R; Dhanvantari, S; Lee, T-Y; Kovacs, M; Luyt, L.
Development of High Affinity Ghrelin(1-8) Analogues for Imaging GHSR-1a with Fluorine-18,
CIHR-STP in Cancer Research & Technology Transfer Research and Education Day, June 23,
2015, London, ON. CA.
Charlton, C.L.; McGirr, B; Dhanvantari, S; Kovacs, M; Luyt, L. Preliminary In Vitro and In
Vivo Evaluation of [68Ga] Labeled Ghrelin(1-19) Analogue for Targeting the Growth Hormone
Secretagogue Receptor, Imaging Applications in Prostate Cancer, November 15, 2013, London,
ON. CA.
Siddiqui, K; Biggs, C; Billia, M; Charlton, C.L.; Mazzola, C; Power, N; Chambers, A; Yang, J;
Luyt, L; Chin, J; Leong, H. Prostate cancer microparticles as a next generation screening tool for
prostate cancer. Society of Urologic Oncology Annual Meeting, 2013, Bethesda, MD.
Charlton, C.L.; McFarland, M.; Dhanvantari, S.; Kovacs, M.; Luyt, L. Ghrelin Analogues as
Non-Invasive Prostate Cancer Imaging Proves. Imaging Applications in Prostate Cancer,
November 2013, London, ON, CA
Charlton, C.L.; McFarland, M.; Dhanvantari, S.; Kovacs, M.; Luyt, L. Ghrelin Analogues as
Non-Invasive Prostate Cancer Imaging Proves. CIHR-STP in Cancer Research & Technology
Transfer Research and Education Day. June 2012, London, ON, CA.

122

MANUSCRIPTS IN PREPARATION
•

•

•

Charron, C. L.; Hou, J.Q.; Kovacs, M.; Luyt, L.G., Design, Synthesis and Radiolabelling of a
High Affinity Ghrelin (1-8) Analogue Bearing a New 6-[18F]fluoronaphthoate Prosthetic Group,
Manuscript in preparation.
Hou, J. Q.; Charron, C. L.; Fowkes, M. M.; Luyt, L. G., Bridging Computational Modeling to
Amino Acid Replacements to Investigate GHSR-1a-Peptidomimetic Recognition, Manuscript in
preparation.
Charron, C. L.; Hou, J.Q.; Groom, H.; McFarland, M.; Luyt, L.G., Development and Evaluation
of [(Dpr3(octanoyl), Lys19(68Ga-DOTA)]-Ghrelin(1-19) for the Detection of GHS-R1a In Vivo,
Manuscript in preparation.

SEMINARS AND ORAL PRESENTATIONS
•

•

“Evaluation of 68Ga-DOTA Ghrelin(1-19) in LNCaP Prostate Carcinoma” presented at the 2nd
International Symposium on Technetium and Other Radiometals in Chemistry and Medicine, on
September 10-13, 2014, Bressanone, Italy.
“The Design of Ghrelin Analogues as PET Imaging Probes for Prostate Cancer” presented at the
Cancer Research Laboratory Program Seminar Series, London Regional Cancer Program, on
November 22, 2012, London, ON, CA.

WORKSHOPS
•

Advanced Molecular Imaging and it’s Clinical Translation on October 27 - 30, 2013, Boston,
MA., USA.

